Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9359302 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(2 years ago) | |
US8642760 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(2 years ago) | |
US8580796 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(2 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8642600 | OTSUKA | Method of treating autism |
Jan, 2022
(3 years ago) | |
US5006528 | OTSUKA | Carbostyril derivatives |
Oct, 2014
(10 years ago) | |
US9089567 | OTSUKA | Method of treating cognitive impairments and schizophrenias |
Jan, 2022
(3 years ago) | |
US7053092 | OTSUKA | 5-HT1a receptor subtype agonist |
Jan, 2022
(3 years ago) | |
US9387182 | OTSUKA | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Dec, 2023
(1 year, 3 months ago) | |
US8642600 (Pediatric) | OTSUKA | Method of treating autism |
Jul, 2022
(2 years ago) | |
US8759350 | OTSUKA | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Mar, 2027
(1 year, 11 months from now) | |
US9125939 | OTSUKA | Carbostyril derivatives and mood stabilizers for treating mood disorders |
Jul, 2026
(1 year, 3 months from now) | |
US8518421 | OTSUKA | Flashmelt oral dosage formulation |
Jan, 2021
(4 years ago) | |
US5006528 (Pediatric) | OTSUKA | Carbostyril derivatives |
Apr, 2015
(9 years ago) | |
US8518421 (Pediatric) | OTSUKA | Flashmelt oral dosage formulation |
Jul, 2021
(3 years ago) | |
US9358207 | OTSUKA | Flashmelt oral dosage formulation |
Apr, 2020
(4 years ago) | |
US8642760 (Pediatric) | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Mar, 2023
(2 years ago) | |
US8580796 (Pediatric) | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Mar, 2023
(2 years ago) | |
US8017615 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Jun, 2024
(9 months ago) | |
US8017615 (Pediatric) | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Dec, 2024
(3 months ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Pediatric Exclusivity(PED) | Aug 27, 2011 |
New Indication(I-616) | Nov 19, 2012 |
New Indication(I-633) | Feb 16, 2014 |
M(M-137) | Jun 09, 2017 |
New Indication(I-700) | Dec 12, 2017 |
Orphan Drug Exclusivity(ODE) | Dec 12, 2021 |
Orphan Drug Exclusivity(ODE-80) | Dec 12, 2021 |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 15 November, 2002
Treatment: Treatment of irritability associated with autistic disorder; Treatment of schizophrenia including maintaining stability in patients with schizophrenia; Treatment of schizophrenia; Treatment of major d...
Dosage: TABLET; TABLET, ORALLY DISINTEGRATING
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US5006528 | OTSUKA PHARM CO LTD | Carbostyril derivatives |
Oct, 2014
(10 years ago) | |
US8993761 | OTSUKA PHARM CO LTD | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(2 years ago) | |
US8399469 | OTSUKA PHARM CO LTD | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Jun, 2025
(3 months from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5006528 (Pediatric) | OTSUKA PHARM CO LTD | Carbostyril derivatives |
Apr, 2015
(9 years ago) | |
US9089567 | OTSUKA PHARM CO LTD | Method of treating cognitive impairments and schizophrenias |
Jan, 2022
(3 years ago) | |
US8759351 | OTSUKA PHARM CO LTD | Methods for administering aripiprazole |
Aug, 2023
(1 year, 7 months ago) | |
US8338428 | OTSUKA PHARM CO LTD | Methods for administering aripiprazole |
Aug, 2023
(1 year, 7 months ago) | |
US5006528 | OTSUKA PHARM CO LTD | Carbostyril derivatives |
Apr, 2015
(9 years ago) | |
US8338427 | OTSUKA PHARM CO LTD | Methods for administering aripiprazole |
Mar, 2025
(13 days ago) | |
US10525057 | OTSUKA PHARM CO LTD | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Mar, 2034
(8 years from now) | |
US11400087 | OTSUKA PHARM CO LTD | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Sep, 2033
(8 years from now) | |
US11154553 | OTSUKA PHARM CO LTD | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Sep, 2033
(8 years from now) | |
US7807680 | OTSUKA PHARM CO LTD | Controlled release sterile injectable aripiprazole formulation and method |
Oct, 2024
(5 months ago) | |
US8722679 | OTSUKA PHARM CO LTD | Controlled release sterile injectable aripiprazole formulation and method |
Oct, 2024
(5 months ago) | |
US11648347 | OTSUKA PHARM CO LTD | Medical device containing a cake composition comprising aripiprazole as an active ingredient, and a cake composition comprising aripiprazole as an active ingredient |
Apr, 2034
(9 years from now) | |
US8030313 | OTSUKA PHARM CO LTD | Controlled release sterile injectable aripiprazole formulation and method |
Oct, 2024
(5 months ago) | |
US11344547 | OTSUKA PHARM CO LTD | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Sep, 2033
(8 years from now) | |
US10980803 | OTSUKA PHARM CO LTD | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Sep, 2033
(8 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosage Form(NDF) | Feb 28, 2016 |
M(M-150) | Dec 05, 2017 |
New Indication(I-746) | Jul 27, 2020 |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 28 February, 2013
Treatment: Treatment of schizophrenia; Use of aripiprazole in extended release injectable suspension; Use of aripiprazole in extended release injectable suspension in treating acute episodes of schizophrenia; Ma...
Dosage: FOR SUSPENSION, EXTENDED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9359302 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(2 years ago) | |
US8580796 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(2 years ago) | |
US8642760 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(2 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9787511 | OTSUKA | Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping |
Sep, 2034
(9 years from now) | |
US9089567 | OTSUKA | Method of treating cognitive impairments and schizophrenias |
Jan, 2022
(3 years ago) | |
US9387182 | OTSUKA | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Dec, 2023
(1 year, 3 months ago) | |
US9270503 | OTSUKA | Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping |
Sep, 2034
(9 years from now) | |
US9577864 | OTSUKA | Method and apparatus for use with received electromagnetic signal at a frequency not known exactly in advance |
Oct, 2033
(8 years from now) | |
US10097388 | OTSUKA | Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping |
Sep, 2034
(9 years from now) | |
US7053092 | OTSUKA | 5-HT1a receptor subtype agonist |
Jan, 2022
(3 years ago) | |
US9125939 | OTSUKA | Carbostyril derivatives and mood stabilizers for treating mood disorders |
Jul, 2026
(1 year, 3 months from now) | |
US8759350 | OTSUKA | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Mar, 2027
(1 year, 11 months from now) | |
US8945005 | OTSUKA | Controlled activation ingestible identifier |
Aug, 2029
(4 years from now) | |
US8674825 | OTSUKA | Pharma-informatics system |
Apr, 2029
(4 years from now) | |
US8956288 | OTSUKA | In-body power source having high surface area electrode |
Jul, 2029
(4 years from now) | |
US8547248 | OTSUKA | Implantable zero-wire communications system |
Dec, 2030
(5 years from now) | |
US8847766 | OTSUKA | Pharma-informatics system |
Mar, 2030
(5 years from now) | |
US9268909 | OTSUKA | Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device |
Oct, 2033
(8 years from now) | |
US9444503 | OTSUKA | Active signal processing personal health signal receivers |
Nov, 2027
(2 years from now) | |
US8017615 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Jun, 2024
(9 months ago) | |
US9433371 | OTSUKA | In-body device with virtual dipole signal amplification |
Sep, 2029
(4 years from now) | |
US9149577 | OTSUKA | Body-associated receiver and method |
Dec, 2029
(4 years from now) | |
US7978064 | OTSUKA | Communication system with partial power source |
Sep, 2026
(1 year, 5 months from now) | |
US9119554 | OTSUKA | Pharma-informatics system |
Dec, 2028
(3 years from now) | |
US8114021 | OTSUKA | Body-associated receiver and method |
Jun, 2030
(5 years from now) | |
US11229378 | OTSUKA | Communication system with enhanced partial power source and method of manufacturing same |
Jul, 2031
(6 years from now) | |
US8718193 | OTSUKA | Active signal processing personal health signal receivers |
Dec, 2029
(4 years from now) | |
US11464423 | OTSUKA | In-body power source having high surface area electrode |
Sep, 2030
(5 years from now) | |
US8258962 | OTSUKA | Multi-mode communication ingestible event markers and systems, and methods of using the same |
Nov, 2030
(5 years from now) | |
US8961412 | OTSUKA | In-body device with virtual dipole signal amplification |
Nov, 2030
(5 years from now) | |
US9060708 | OTSUKA | Multi-mode communication ingestible event markers and systems, and methods of using the same |
Mar, 2029
(3 years from now) | |
US10441194 | OTSUKA | Ingestible event marker systems |
Jul, 2029
(4 years from now) | |
US9320455 | OTSUKA | Highly reliable ingestible event markers and methods for using the same |
Dec, 2031
(6 years from now) | |
US9258035 | OTSUKA | Multi-mode communication ingestible event markers and systems, and methods of using the same |
Mar, 2029
(3 years from now) | |
US11476952 | OTSUKA | Pharma-informatics system |
Apr, 2026
(1 year, 30 days from now) | |
US10517507 | OTSUKA | Communication system with enhanced partial power source and method of manufacturing same |
Jun, 2032
(7 years from now) | |
US8545402 | OTSUKA | Highly reliable ingestible event markers and methods for using the same |
Apr, 2030
(5 years from now) | |
US9941931 | OTSUKA | System for supply chain management |
Nov, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-150) | Dec 05, 2017 |
New Indication(I-746) | Jul 27, 2020 |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 13 November, 2017
Treatment: Method of using a receiver to identify a signal from a tablet embedded with a sensor that communicates information through the body of a patient; Treatment of schizophrenia; Adjunctive treatment of ma...
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9687487 | ALEXZA PHARMS | Aerosol forming device for use in inhalation therapy |
Oct, 2021
(3 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9440034 | ALEXZA PHARMS | Drug condensation aerosols and kits |
Oct, 2021
(3 years ago) | |
US7090830 | ALEXZA PHARMS | Drug condensation aerosols and kits |
Oct, 2021
(3 years ago) | |
US7585493 | ALEXZA PHARMS | Thin-film drug delivery article and method of use |
Oct, 2021
(3 years ago) | |
US7052679 | ALEXZA PHARMS | Delivery of antipsychotics through an inhalation route |
Mar, 2022
(3 years ago) | |
US7078020 | ALEXZA PHARMS | Delivery of antipsychotics through an inhalation route |
Oct, 2021
(3 years ago) | |
US7601337 | ALEXZA PHARMS | Delivery of antipsychotics through an inhalation route |
Oct, 2021
(3 years ago) | |
US8074644 | ALEXZA PHARMS | Method of forming an aerosol for inhalation delivery |
Oct, 2021
(3 years ago) | |
US8955512 | ALEXZA PHARMS | Method of forming an aerosol for inhalation delivery |
Oct, 2021
(3 years ago) | |
US6716416 | ALEXZA PHARMS | Delivery of antipsychotics through an inhalation route |
May, 2022
(2 years ago) | |
US9439907 | ALEXZA PHARMS | Method of forming an aerosol for inhalation delivery |
Oct, 2021
(3 years ago) | |
US8173107 | ALEXZA PHARMS | Delivery of antipsychotics through an inhalation route |
Oct, 2021
(3 years ago) | |
US8235037 | ALEXZA PHARMS | Drug condensation aerosols and kits |
Oct, 2021
(3 years ago) | |
US8991387 | ALEXZA PHARMS | Self-contained heating unit and drug-supply unit employing same |
May, 2024
(10 months ago) | |
US9370629 | ALEXZA PHARMS | Self-contained heating unit and drug-supply unit employing same |
May, 2024
(10 months ago) | |
US7458374 | ALEXZA PHARMS | Method and apparatus for vaporizing a compound |
Aug, 2024
(7 months ago) | |
US8387612 | ALEXZA PHARMS | Self-contained heating unit and drug-supply unit employing same |
Oct, 2026
(1 year, 6 months from now) | |
US7537009 | ALEXZA PHARMS | Method of forming an aerosol for inhalation delivery |
Oct, 2024
(4 months ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosage Form(NDF) | Dec 21, 2015 |
Drugs and Companies using LOXAPINE ingredient
Market Authorisation Date: 21 December, 2012
Treatment: Adasuve is a typical antipsychotic indicated for the acute treatment of agitation associated with schizophrenia or bipolar i disorder in adults
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7420057 | SPROUT PHARMS | Stable polymorph of flibanserin |
Aug, 2022
(2 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8227471 | SPROUT PHARMS | Treating sexual desire disorders with flibanserin |
May, 2023
(1 year, 10 months ago) | |
US9468639 | SPROUT PHARMS | Treating sexual desire disorders with flibanserin |
Oct, 2022
(2 years ago) | |
US7151103 | SPROUT PHARMS | Method of treating female hypoactive sexual desire disorder with flibanserin |
May, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Aug 18, 2020 |
Drugs and Companies using FLIBANSERIN ingredient
NCE-1 date: 19 August, 2019
Market Authorisation Date: 18 August, 2015
Treatment: Use of flibanserin or a pharmaceutically acceptable acid addition salt thereof to treat hypoactive sexual desire disorder (hsdd)
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
USRE45313 | SANOFI-AVENTIS US | Exendin variant peptides |
Jul, 2020
(4 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9821032 | SANOFI-AVENTIS US | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
May, 2032
(7 years from now) | |
US10201663 | SANOFI-AVENTIS US | Assembly for a drug delivery device |
Mar, 2034
(8 years from now) | |
US8475414 | SANOFI-AVENTIS US | Medication delivery device and method for operating a medication delivery device |
Dec, 2030
(5 years from now) | |
US9308329 | SANOFI-AVENTIS US | Medication delivery device and method for operating a medication delivery device |
Dec, 2030
(5 years from now) | |
US8915888 | SANOFI-AVENTIS US | Dosing and drive mechanism for drug delivery device |
Jun, 2030
(5 years from now) | |
US9981013 | SANOFI-AVENTIS US | Use of AVE0010 for the treatment of diabetes mellitus type 2 |
Aug, 2030
(5 years from now) | |
US9408893 | SANOFI-AVENTIS US | Pharmaceutical combination for use in glycemic control in diabetes type 2 patients |
Aug, 2032
(7 years from now) | |
US9084853 | SANOFI-AVENTIS US | Drive mechanism for a drug delivery device and drug delivery device |
Oct, 2031
(6 years from now) | |
US9855388 | SANOFI-AVENTIS US | Dosing and drive mechanism for drug delivery device |
Apr, 2029
(4 years from now) | |
US9072836 | SANOFI-AVENTIS US | Drive mechanism for a drug delivery device and drug delivery device |
Mar, 2032
(6 years from now) | |
US9440029 | SANOFI-AVENTIS US | Drive mechanism for a drug delivery device and drug delivery device |
Jan, 2032
(6 years from now) | |
US9511193 | SANOFI-AVENTIS US | Assembly and indicator for a drug delivery device |
Jan, 2032
(6 years from now) | |
US9707176 | SANOFI-AVENTIS US | Pharmaceutical composition comprising a GLP-1 agonist and methionine |
Nov, 2030
(5 years from now) | |
US10028910 | SANOFI-AVENTIS US | Pharmaceutical composition comprising a GLP-1-agonist and methionine |
Nov, 2030
(5 years from now) | |
US8882721 | SANOFI-AVENTIS US | Drive assembly suitable for use in a drug delivery device and drug delivery device |
Jun, 2031
(6 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jul 27, 2021 |
Drugs and Companies using LIXISENATIDE ingredient
NCE-1 date: 27 July, 2020
Market Authorisation Date: 27 July, 2016
Treatment: Combination treatment with insulin glargine with or without metformin for improvement of glycemic control in type 2 diabetes mellitus patients; Improvement in glycemic control in type 2 diabetes melli...
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US5733919 | MEDICURE | Compositions for inhibiting platelet aggregation |
Oct, 2016
(8 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6136794 | MEDICURE | Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist |
Jan, 2019
(6 years ago) | |
US5978698 | MEDICURE | Angioplasty procedure using nonionic contrast media |
Oct, 2017
(7 years ago) | |
US5733919 | MEDICURE | Compositions for inhibiting platelet aggregation |
Oct, 2016
(8 years ago) | |
US5972967 | MEDICURE | Compositions for inhibiting platelet aggregation |
Oct, 2016
(8 years ago) | |
US5965581 | MEDICURE | Compositions for inhibiting platelet aggregation |
Oct, 2016
(8 years ago) | |
US6770660 | MEDICURE | Method for inhibiting platelet aggregation |
May, 2023
(1 year, 10 months ago) |
Drugs and Companies using TIROFIBAN HYDROCHLORIDE ingredient
Market Authorisation Date: 14 May, 1998
Treatment: A dosing regimen of aggrastat (tirofiban hydrochloride)(25mcg/kg followed by 0.15mcg/kg/min infusion) to reduce the rate of thrombotic coronary events associated with acute coronary syndrome (acs) in ...
Dosage: SOLUTION; INJECTABLE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8658673 | NOVARTIS | BETA2-adrenoreceptor agonists |
Jun, 2020
(4 years ago) | |
US8796307 | NOVARTIS | Beta2-adrenoreceptor agonists |
Jun, 2020
(4 years ago) | |
US6878721 | NOVARTIS | Beta2-adrenoceptor agonists |
Feb, 2025
(a month ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8067437 | NOVARTIS | Beta-2-adrenoreceptor agonists |
Jun, 2020
(4 years ago) | |
US8479730 | NOVARTIS | Inhaler device |
Oct, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jul 01, 2016 |
Drugs and Companies using INDACATEROL MALEATE ingredient
NCE-1 date: 02 July, 2015
Market Authorisation Date: 01 July, 2011
Treatment: The long term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7101866 | GLAXOSMITHKLINE | Anti-inflammatory androstane derivative |
Aug, 2021
(3 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8113199 | GLAXOSMITHKLINE | Counter for use with a medicament dispenser |
Oct, 2027
(2 years from now) | |
US5873360 | GLAXOSMITHKLINE | Inhalation device |
Feb, 2016
(9 years ago) | |
US7629335 | GLAXOSMITHKLINE | Anti-inflammatory androstane derivative |
Aug, 2021
(3 years ago) | |
US8161968 | GLAXOSMITHKLINE | Medicament dispenser |
Feb, 2028
(2 years from now) | |
US8161968 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Aug, 2028
(3 years from now) | |
US8113199 (Pediatric) | GLAXOSMITHKLINE | Counter for use with a medicament dispenser |
Apr, 2028
(3 years from now) | |
US8534281 (Pediatric) | GLAXOSMITHKLINE | Manifold for use in medicament dispenser |
Sep, 2030
(5 years from now) | |
US8534281 | GLAXOSMITHKLINE | Manifold for use in medicament dispenser |
Mar, 2030
(4 years from now) | |
US8201556 | GLAXOSMITHKLINE | Medicament dispenser |
Feb, 2029
(3 years from now) | |
US9333310 | GLAXOSMITHKLINE | Medicament dispenser |
Oct, 2027
(2 years from now) | |
US8746242 | GLAXOSMITHKLINE | Medicament dispenser |
Oct, 2030
(5 years from now) | |
US8746242 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Apr, 2031
(6 years from now) | |
US9333310 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Apr, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Aug 20, 2017 |
New Patient Population(NPP) | May 17, 2021 |
New Strength(NS) | May 17, 2021 |
M(M-290) | Mar 01, 2026 |
Drugs and Companies using FLUTICASONE FUROATE ingredient
Market Authorisation Date: 17 May, 2018
Treatment: Indicated for the once-daily maintenance treatment of asthma as prophylactic therapy in patients aged 12 years of age and older
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9328133 | KERYX BIOPHARMS | Ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(1 year, 1 month ago) | |
US8338642 | KERYX BIOPHARMS | Ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(1 year, 1 month ago) | |
US9757416 | KERYX BIOPHARMS | Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(1 year, 1 month ago) | |
US7767851 | KERYX BIOPHARMS | Ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(1 year, 1 month ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5753706 | KERYX BIOPHARMS | Methods for treating renal failure |
Feb, 2022
(3 years ago) | |
US8093423 | KERYX BIOPHARMS | Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same |
Apr, 2026
(1 year, 23 days from now) | |
US10300039 | KERYX BIOPHARMS | Ferric citrate dosage forms |
Jul, 2030
(5 years from now) | |
US8846976 | KERYX BIOPHARMS | Ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(1 year, 1 month ago) | |
US8901349 | KERYX BIOPHARMS | Ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(1 year, 1 month ago) | |
US8609896 | KERYX BIOPHARMS | Ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(1 year, 1 month ago) | |
US9387191 | KERYX BIOPHARMS | Ferric citrate dosage forms |
Jul, 2030
(5 years from now) | |
US8299298 | KERYX BIOPHARMS | Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same |
Feb, 2024
(1 year, 1 month ago) | |
US8754258 | KERYX BIOPHARMS | Ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(1 year, 1 month ago) | |
US8754257 | KERYX BIOPHARMS | Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(1 year, 1 month ago) | |
US9050316 | KERYX BIOPHARMS | Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(1 year, 1 month ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-790) | Nov 06, 2020 |
Drugs and Companies using FERRIC CITRATE ingredient
Market Authorisation Date: 05 September, 2014
Treatment: Control of serum phosphorous levels; Control of serum phosphorus levels
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US5808146 | BLUE EARTH | Amino acid analogs for tumor imaging |
Nov, 2020
(4 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10716868 | BLUE EARTH | Imaging of metastatic or recurrent cancer |
Dec, 2035
(10 years from now) | |
US10967077 | BLUE EARTH | Imaging of metastatic or recurrent cancer |
Dec, 2035
(10 years from now) | |
US10953112 | BLUE EARTH | Precursor compound of radioactive halogen-labeled organic compound |
Nov, 2026
(1 year, 8 months from now) | |
US10933147 | BLUE EARTH | Imaging of metastatic or recurrent cancer |
Dec, 2035
(10 years from now) | |
US9387266 | BLUE EARTH | Precursor compound of radioactive halogen-labeled organic compound |
Nov, 2026
(1 year, 8 months from now) | |
US10010632 | BLUE EARTH | Precursor compound of radioactive halogen-labeled organic compound |
Nov, 2026
(1 year, 8 months from now) | |
US10124079 | BLUE EARTH | Imaging of metastatic or recurrent cancer |
Dec, 2035
(10 years from now) | |
US11980674 | BLUE EARTH | Imaging of metastatic or recurrent cancer |
Apr, 2042
(17 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | May 27, 2021 |
Drugs and Companies using FLUCICLOVINE F-18 ingredient
NCE-1 date: 27 May, 2020
Market Authorisation Date: 27 May, 2016
Treatment: Positron emission tomography diagnostic agent in adults with suspected prostate cancer recurrence based on elevated blood prostate specific antigen levels following prior treatment; Method of diagnosi...
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7250419 | ASTRAZENECA | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition |
Dec, 2019
(5 years ago) | |
US7265124 | ASTRAZENECA | Cristalline and amorphous form of a triazolo (4,5-D) pyridimine compound |
Jul, 2021
(3 years ago) | |
US6525060 | ASTRAZENECA | Triazolo(4,5-d)pyrimidine compounds |
Dec, 2019
(5 years ago) | |
US6251910 | ASTRAZENECA | 1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists |
Jul, 2018
(6 years ago) | |
USRE46276 | ASTRAZENECA | Triazolo(4,5-D)pyrimidine compounds |
Oct, 2024
(4 months ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6525060 | ASTRAZENECA | Triazolo(4,5-d)pyrimidine compounds |
Dec, 2019
(5 years ago) | |
US6251910 | ASTRAZENECA | 1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists |
Jul, 2018
(6 years ago) | |
US7250419 | ASTRAZENECA | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition |
Dec, 2019
(5 years ago) | |
US7265124 | ASTRAZENECA | Cristalline and amorphous form of a triazolo (4,5-D) pyridimine compound |
Jul, 2021
(3 years ago) | |
US10300065 | ASTRAZENECA | Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction |
Jan, 2036
(10 years from now) | |
US8425934 | ASTRAZENECA | Pharmaceutical compositions |
Apr, 2030
(5 years from now) | |
US8425934 (Pediatric) | ASTRAZENECA | Pharmaceutical compositions |
Oct, 2030
(5 years from now) | |
USRE46276 (Pediatric) | ASTRAZENECA | Triazolo(4,5-D)pyrimidine compounds |
Apr, 2025
(a month from now) | |
US10300065 (Pediatric) | ASTRAZENECA | Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction |
Jul, 2036
(11 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jul 20, 2016 |
New Indication(I-714) | Sep 03, 2018 |
New Strength(NS) | Sep 03, 2018 |
New Indication(I-851) | May 28, 2023 |
New Indication(I-848) | Nov 05, 2023 |
M(M-283) | May 09, 2025 |
Pediatric Exclusivity(PED) | Nov 09, 2025 |
Drugs and Companies using TICAGRELOR ingredient
NCE-1 date: 09 November, 2024
Market Authorisation Date: 03 September, 2015
Treatment: Reduction of the rate of thrombotic events in patients with acute coronary syndrome; Reducing the rate of cardiovascular death, myocardial infarction, and stroke in a patient receiving 75-100 mg aspir...
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US5712298 | ASTRAZENECA | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors |
Jan, 2020
(5 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8536206 | ASTRAZENECA | Process for the preparation of roflumilast |
Mar, 2024
(1 year, 20 days ago) | |
US8431154 | ASTRAZENECA | Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient |
Feb, 2023
(2 years ago) | |
US9468598 | ASTRAZENECA | Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient |
Feb, 2023
(2 years ago) | |
US5712298 | ASTRAZENECA | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors |
Jan, 2015
(10 years ago) | |
US8604064 | ASTRAZENECA | Process for the preparation of roflumilast |
Mar, 2024
(1 year, 20 days ago) | |
US8618142 | ASTRAZENECA | Process for the preparation of roflumilast |
Mar, 2024
(1 year, 20 days ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Feb 28, 2016 |
M(M-208) | Aug 31, 2020 |
New Dosing Schedule(D-171) | Jan 23, 2021 |
New Strength(NS) | Jan 23, 2021 |
Drugs and Companies using ROFLUMILAST ingredient
NCE-1 date: 28 February, 2015
Market Authorisation Date: 23 January, 2018
Treatment: Treatment to reduce the risk of copd exacerbations in patients with severe copd associated with chronic bronchitis and a history of exacerbations
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9145389 | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jun, 2020
(4 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6939971 | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jun, 2020
(4 years ago) | |
US6462058 | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jun, 2020
(4 years ago) | |
US8784885 | TAKEDA PHARMS USA | Controlled release preparation |
Oct, 2023
(1 year, 5 months ago) | |
US6664276 | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jun, 2020
(4 years ago) | |
US7285668 | TAKEDA PHARMS USA | Process for the crystallization of (R)- or (S)-lansoprazole |
Jun, 2020
(4 years ago) | |
US7285668 (Pediatric) | TAKEDA PHARMS USA | Process for the crystallization of (R)- or (S)-lansoprazole |
Dec, 2020
(4 years ago) | |
US6462058 (Pediatric) | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Dec, 2020
(4 years ago) | |
US6939971 (Pediatric) | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Dec, 2020
(4 years ago) | |
US8722084 | TAKEDA PHARMS USA | Controlled release preparation |
Oct, 2023
(1 year, 5 months ago) | |
US6664276 (Pediatric) | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Dec, 2020
(4 years ago) | |
US9233103 | TAKEDA PHARMS USA | Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy |
Mar, 2032
(6 years from now) | |
US8173158 | TAKEDA PHARMS USA | Methods of treating gastrointestinal disorders independent of the intake of food |
Mar, 2030
(4 years from now) | |
US9011926 | TAKEDA PHARMS USA | Method for producing granules |
Feb, 2026
(10 months from now) | |
US7790755 | TAKEDA PHARMS USA | Controlled release preparation |
Aug, 2026
(1 year, 4 months from now) | |
US8871273 | TAKEDA PHARMS USA | Method for producing granules |
Jan, 2028
(2 years from now) | |
US9238029 | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jan, 2026
(9 months from now) | |
US8105626 | TAKEDA PHARMS USA | Granules containing acid-unstable chemical in large amount |
Sep, 2026
(1 year, 5 months from now) | |
US8461187 | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jan, 2026
(9 months from now) | |
US8784885 (Pediatric) | TAKEDA PHARMS USA | Controlled release preparation |
Apr, 2024
(11 months ago) | |
US8722084 (Pediatric) | TAKEDA PHARMS USA | Controlled release preparation |
Apr, 2024
(11 months ago) | |
US7790755 (Pediatric) | TAKEDA PHARMS USA | Controlled release preparation |
Feb, 2027
(1 year, 10 months from now) | |
US8105626 (Pediatric) | TAKEDA PHARMS USA | Granules containing acid-unstable chemical in large amount |
Mar, 2027
(1 year, 11 months from now) | |
US8173158 (Pediatric) | TAKEDA PHARMS USA | Methods of treating gastrointestinal disorders independent of the intake of food |
Sep, 2030
(5 years from now) | |
US8461187 (Pediatric) | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jul, 2026
(1 year, 3 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Jan 30, 2012 |
Pediatric Exclusivity(PED) | Jul 30, 2012 |
New Patient Population(NPP) | Jul 08, 2019 |
Drugs and Companies using DEXLANSOPRAZOLE ingredient
Market Authorisation Date: 30 January, 2009
Treatment: Healing of all grades of erosive esophagitis (ee) for up to 8 weeks; Maintain healing of erosive esophagitis (ee) for up to 6 months; For the treatment of heartburn associated with symptomatic non-ero...
Dosage: CAPSULE, DELAYED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6462058 | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jun, 2020
(4 years ago) | |
US9145389 | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jun, 2020
(4 years ago) | |
US7285668 | TAKEDA PHARMS USA | Process for the crystallization of (R)- or (S)-lansoprazole |
Jun, 2020
(4 years ago) | |
US6664276 | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jan, 2023
(2 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7399485 | TAKEDA PHARMS USA | Rapidly Disintegrable solid preparation |
May, 2018
(6 years ago) | |
US6238994 (Pediatric) | TAKEDA PHARMS USA | Method of creating a rough electrode (high surface area) from Ti and TiN and resulting article |
Nov, 2019
(5 years ago) | |
US7399485 (Pediatric) | TAKEDA PHARMS USA | Rapidly Disintegrable solid preparation |
Nov, 2018
(6 years ago) | |
US6939971 (Pediatric) | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Dec, 2020
(4 years ago) | |
US7285668 (Pediatric) | TAKEDA PHARMS USA | Process for the crystallization of (R)- or (S)-lansoprazole |
Dec, 2020
(4 years ago) | |
US6328994 | TAKEDA PHARMS USA | Orally disintegrable tablets |
May, 2019
(5 years ago) | |
US6939971 | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jun, 2020
(4 years ago) | |
US6238994 | TAKEDA PHARMS USA | Method of creating a rough electrode (high surface area) from Ti and TiN and resulting article |
May, 2019
(5 years ago) | |
US7875292 | TAKEDA PHARMS USA | Orally disintegrable tablets |
May, 2019
(5 years ago) | |
US7431942 | TAKEDA PHARMS USA | Orally disintegrable tablets |
May, 2019
(5 years ago) | |
US8784885 | TAKEDA PHARMS USA | Controlled release preparation |
Oct, 2023
(1 year, 5 months ago) | |
US6328994 (Pediatric) | TAKEDA PHARMS USA | Orally disintegrable tablets |
Nov, 2019
(5 years ago) | |
US7875292 (Pediatric) | TAKEDA PHARMS USA | Orally disintegrable tablets |
Nov, 2019
(5 years ago) | |
US7431942 (Pediatric) | TAKEDA PHARMS USA | Orally disintegrable tablets |
Nov, 2019
(5 years ago) | |
US6462058 (Pediatric) | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Dec, 2020
(4 years ago) | |
US6664276 (Pediatric) | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jul, 2023
(1 year, 7 months ago) | |
US9238029 | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jan, 2026
(9 months from now) | |
US8461187 | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jan, 2026
(9 months from now) | |
US9011926 | TAKEDA PHARMS USA | Method for producing granules |
Feb, 2026
(10 months from now) | |
US9241910 | TAKEDA PHARMS USA | Orally-disintegrating solid preparation |
Mar, 2029
(3 years from now) | |
US8871273 | TAKEDA PHARMS USA | Method for producing granules |
Jan, 2028
(2 years from now) | |
US8784885 (Pediatric) | TAKEDA PHARMS USA | Controlled release preparation |
Apr, 2024
(11 months ago) | |
US8461187 (Pediatric) | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jul, 2026
(1 year, 3 months from now) | |
US8871273 (Pediatric) | TAKEDA PHARMS USA | Method for producing granules |
Jul, 2028
(3 years from now) |
Drugs and Companies using DEXLANSOPRAZOLE ingredient
Market Authorisation Date: 26 January, 2016
Treatment: Treatment of heartburn associated with non-erosive gastroesophageal reflux disease (gerd) for 4 weeks; Maintain healing of erosive esophagitis (ee) for up to 6 months
Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7078412 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(4 years ago) | |
USRE46417 | COVIS | Quinuclidine derivatives and their use as muscarinic M3 receptor ligands |
Feb, 2025
(a month ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10034867 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(4 years ago) | |
US9333195 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(4 years ago) | |
US10588895 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(4 years ago) | |
US8129405 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(4 years ago) | |
US9056100 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(4 years ago) | |
US7750023 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(4 years ago) | |
US6681768 | COVIS | Powder formulation disintegrating system and method for dry powder inhalers |
Aug, 2022
(2 years ago) | |
US10085974 | COVIS | Dosage and formulation |
Mar, 2029
(3 years from now) | |
US11000517 | COVIS | Dosage and formulation |
Mar, 2029
(3 years from now) | |
US8051851 | COVIS | Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhaler |
Apr, 2027
(2 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Combination(NC) | Mar 29, 2022 |
Drugs and Companies using ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE ingredient
Market Authorisation Date: 29 March, 2019
Treatment: Maintenance treatment of chronic obstructive pulmonary disease (copd); Maintenance treatment of chronic pulmonary disease (copd)
Dosage: POWDER, METERED
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6096742 | MSD MERCK CO | Polymorphic form of a tachykinin receptor antagonist |
Jul, 2018
(6 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8258132 | MSD MERCK CO | Pharmaceutical composition of a tachykinin receptor antagonist |
Sep, 2027
(2 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jan 25, 2013 |
M(M-82) | Mar 19, 2013 |
New Dosing Schedule(D-128) | Nov 12, 2013 |
New Patient Population(NPP) | Apr 03, 2021 |
New Dosing Schedule(D-155) | Feb 01, 2019 |
Pediatric Exclusivity(PED) | Oct 03, 2021 |
New Dosing Schedule(D-186) | May 02, 2025 |
Drugs and Companies using APREPITANT ingredient
Market Authorisation Date: 17 December, 2015
Treatment: Prevention of nausea and vomiting associated with chemotherapy (cinv)
Dosage: FOR SUSPENSION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US5905082 | VIIV HLTHCARE | Crystalline oxathiolane derivatives |
May, 2016
(8 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6004968 | VIIV HLTHCARE | Pharmaceutical compositions containing lamivudine |
Mar, 2018
(7 years ago) | |
US5905082 (Pediatric) | VIIV HLTHCARE | Crystalline oxathiolane derivatives |
Nov, 2016
(8 years ago) | |
US6004968 (Pediatric) | VIIV HLTHCARE | Pharmaceutical compositions containing lamivudine |
Sep, 2018
(6 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosing Schedule(D-147) | Mar 23, 2018 |
Drugs and Companies using LAMIVUDINE ingredient
Market Authorisation Date: 17 November, 1995
Treatment: NA
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7101866 | HALEON US HOLDINGS | Anti-inflammatory androstane derivative |
Aug, 2021
(3 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6858596 | HALEON US HOLDINGS | Formulation containing anti-inflammatory androstane derivative |
Aug, 2021
(3 years ago) | |
US7541350 | HALEON US HOLDINGS | Formulation containing anti-inflammatory androstane derivative |
Aug, 2021
(3 years ago) | |
US8752543 | HALEON US HOLDINGS | Fluid dispensing device |
Apr, 2026
(1 year, 7 days from now) | |
US9320862 | HALEON US HOLDINGS | Fluid dispensing device |
Nov, 2024
(4 months ago) | |
US8347879 | HALEON US HOLDINGS | Fluid dispensing device |
Jul, 2028
(3 years from now) | |
US8062264 | HALEON US HOLDINGS | Fluid dispensing device |
Apr, 2026
(1 year, 7 days from now) | |
US8147461 | HALEON US HOLDINGS | Fluid dispensing device |
Oct, 2028
(3 years from now) |
Drugs and Companies using FLUTICASONE FUROATE ingredient
Market Authorisation Date: 27 April, 2007
Treatment: Otc use: allergy symptom reliever; Temporarily relieves these symptoms due to hay fever or other upper respiratory allergies; Nasal congestion, runny nose, sneezing, itchy nose, and (itchy water eyes ...
Dosage: SPRAY, METERED
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US5980864 | BAYER HLTHCARE | 1,4,7,10-tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them |
Nov, 2021
(3 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5980864 | BAYER HLTHCARE | 1,4,7,10-tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them |
Nov, 2016
(8 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Mar 14, 2016 |
New Indication(I-688) | Jun 11, 2017 |
New Indication(I-731) | Apr 27, 2019 |
New Indication(I-801) | Jul 12, 2022 |
Drugs and Companies using GADOBUTROL ingredient
NCE-1 date: 15 March, 2015
Market Authorisation Date: 18 December, 2013
Treatment: Contrast agent for magnetic resonance imaging
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US5604229 | NOVARTIS | 2-amino-1,3-propanediol compound and immunosuppressant |
Feb, 2019
(6 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6004565 | NOVARTIS | Compositions and methods of using compositions with accelerated lymphocyte homing immunosuppressive properties |
Sep, 2017
(7 years ago) | |
US5604229 (Pediatric) | NOVARTIS | 2-amino-1,3-propanediol compound and immunosuppressant |
Aug, 2019
(5 years ago) | |
US5604229 | NOVARTIS | 2-amino-1,3-propanediol compound and immunosuppressant |
Feb, 2014
(11 years ago) | |
US10543179 | NOVARTIS | Dosage regimen of an S1P receptor modulator |
Dec, 2027
(2 years from now) | |
US9592208 | NOVARTIS | Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol |
Mar, 2032
(7 years from now) | |
US9187405 | NOVARTIS | S1P receptor modulators for treating relasping-remitting multiple sclerosis |
Jun, 2027
(2 years from now) | |
US9592208 (Pediatric) | NOVARTIS | Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol |
Sep, 2032
(7 years from now) | |
US8324283 | NOVARTIS | Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol |
Mar, 2026
(a year from now) | |
US8324283 (Pediatric) | NOVARTIS | Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol |
Sep, 2026
(1 year, 6 months from now) | |
US9187405 (Pediatric) | NOVARTIS | S1P receptor modulators for treating relasping-remitting multiple sclerosis |
Dec, 2027
(2 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-106) | Jul 20, 2014 |
New Chemical Entity Exclusivity(NCE) | Sep 21, 2015 |
New Patient Population(NPP) | May 11, 2021 |
New Strength(NS) | May 11, 2021 |
Pediatric Exclusivity(PED) | Nov 11, 2021 |
Drugs and Companies using FINGOLIMOD HYDROCHLORIDE ingredient
NCE-1 date: 11 November, 2020
Market Authorisation Date: 11 May, 2018
Treatment: Treatment of autoimmune disease; Treatment of relapsing remitting multiple sclerosis by determining varicella zoster virus (vzv) status and vaccinating prior to commencing treatment; Treatment of mult...
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7943661 | IPSEN | Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof |
Sep, 2024
(6 months ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US12233038 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(12 years from now) | |
US7632870 | IPSEN | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof |
Sep, 2024
(6 months ago) | |
US11857523 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(12 years from now) | |
US11850223 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(12 years from now) | |
US11331292 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(12 years from now) | |
US11185519 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jun 10, 2029 |
Orphan Drug Exclusivity(ODE-486) | Jun 10, 2031 |
Drugs and Companies using ELAFIBRANOR ingredient
NCE-1 date: 10 June, 2028
Market Authorisation Date: 10 June, 2024
Treatment: Treatment of primary biliary cholangitis (pbc); Treatment of primary biliary cholangitis (pbc) in combination with ursodeoxycholic acid (udca) in adults who have had an inadequate response to udca, or...
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US5770599 | ASTRAZENECA | Quinazoline derivatives |
May, 2017
(7 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Jul 13, 2018 |
Orphan Drug Exclusivity(ODE) | Jul 13, 2022 |
Orphan Drug Exclusivity(ODE-95) | Jul 13, 2022 |
Drugs and Companies using GEFITINIB ingredient
Market Authorisation Date: 13 July, 2015
Treatment: First-line treatment of patients with metastatic non-small cell lung cancer (nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutation...
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6465504 | NOVARTIS | Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators |
Apr, 2019
(5 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-239) | Dec 12, 2021 |
M(M-241) | Jul 24, 2022 |
M(M-263) | Jul 23, 2023 |
Drugs and Companies using DEFERASIROX ingredient
Market Authorisation Date: 18 May, 2017
Treatment: NA
Dosage: GRANULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US5712279 | CHIESI | Inhibitors of microsomal triglyceride transfer protein and method |
Feb, 2020
(5 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5739135 | CHIESI | Inhibitors of microsomal triglyceride transfer protein and method |
Apr, 2015
(9 years ago) | |
US6492365 | CHIESI | Microsomal triglyceride transfer protein |
Dec, 2019
(5 years ago) | |
US5712279 | CHIESI | Inhibitors of microsomal triglyceride transfer protein and method |
Feb, 2015
(10 years ago) | |
US7932268 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
Aug, 2027
(2 years from now) | |
US8618135 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
Mar, 2025
(21 days ago) | |
US9433617 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
Mar, 2025
(21 days ago) | |
US9265758 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
Mar, 2025
(21 days ago) | |
US9364470 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
Mar, 2025
(21 days ago) | |
US9861622 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
Mar, 2025
(21 days ago) | |
US10016404 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
Mar, 2025
(21 days ago) | |
US10555938 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
Mar, 2025
(21 days ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Dec 21, 2017 |
Orphan Drug Exclusivity(ODE) | Dec 21, 2019 |
Orphan Drug Exclusivity(ODE-36) | Dec 21, 2019 |
Drugs and Companies using LOMITAPIDE MESYLATE ingredient
NCE-1 date: 21 December, 2016
Market Authorisation Date: 21 December, 2012
Treatment: Treatment of hypercholesterolemia, hyperlipidemia and hyperlipoproteinemia in patients with homozygous familial hypercholesterolemia; Treatment of hypercholesterolemia by decreasing the amount or acti...
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
USRE47351 | ASTELLAS | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists |
Jun, 2019
(5 years ago) | |
US8106183 | ASTELLAS | Process for preparing an A2A-adenosine receptor agonist and its polymorphs |
Feb, 2027
(1 year, 10 months from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8536150 | ASTELLAS | Methods of myocardial perfusion imaging |
Jun, 2019
(5 years ago) | |
US8470801 | ASTELLAS | Myocardial perfusion imaging methods and compositions |
Jun, 2019
(5 years ago) | |
US8106029 | ASTELLAS | Use of A2A adenosine receptor agonists |
Jun, 2019
(5 years ago) | |
US7655637 | ASTELLAS | N-pyrazole A2A receptor agonists |
Jun, 2019
(5 years ago) | |
US7683037 | ASTELLAS | Myocardial perfusion imaging method |
Jun, 2019
(5 years ago) | |
US7655636 | ASTELLAS | Use of A2A adenosine receptor agonists |
Jun, 2019
(5 years ago) | |
US7582617 | ASTELLAS | Myocardial perfusion imaging method |
Jun, 2019
(5 years ago) | |
US9289446 | ASTELLAS | Myocardial perfusion imaging methods and compositions |
Jun, 2019
(5 years ago) | |
US7144872 | ASTELLAS | N-pyrazole A2A receptor agonists |
Jun, 2019
(5 years ago) | |
US6642210 | ASTELLAS | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists |
Jun, 2019
(5 years ago) | |
US9085601 | ASTELLAS | Process for preparing an A2A-adenosine receptor agonist and its polymorphs |
Feb, 2027
(1 year, 10 months from now) | |
US9045519 | ASTELLAS | N-pyrazole A2A receptor agonists |
Jun, 2019
(5 years ago) | |
US8183226 | ASTELLAS | Myocardial perfusion imaging method |
Jun, 2019
(5 years ago) | |
US7183264 | ASTELLAS | N-pyrazole A2A receptor agonists |
Jun, 2019
(5 years ago) | |
US6403567 | ASTELLAS | N-pyrazole A2A adenosine receptor agonists |
Apr, 2022
(2 years ago) | |
US8133879 | ASTELLAS | Myocardial perfusion imaging methods and compositions |
Jun, 2019
(5 years ago) | |
USRE47301 | ASTELLAS | Process for preparing an A2A-adenosine receptor agonist and its polymorphs |
Feb, 2027
(1 year, 10 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Apr 10, 2013 |
M(M-194) | Jan 17, 2020 |
Drugs and Companies using REGADENOSON ingredient
NCE-1 date: 10 April, 2012
Market Authorisation Date: 10 April, 2008
Treatment: Method of myocardial imaging; Method for stimulating coronary vasodilation for purposes of imaging the heart; A method of myocardial perfusion imaging and increasing coronary blood flow; Method of pro...
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US5686060 | BRACCO | Stable microbubble suspensions comprising saturated phospholipids for ultrasound echography |
Nov, 2019
(5 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11723869 | BRACCO | Freeze-dried product and gas-filled microvesicles suspension |
May, 2039
(14 years from now) | |
US10232061 | BRACCO | Freeze-dried formulation for gas-filled microvesicles |
Jul, 2038
(13 years from now) | |
US10335502 | BRACCO | Freeze-dried formulation for gas-filled microvesicles |
Jul, 2038
(13 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-728) | Mar 31, 2019 |
New Chemical Entity Exclusivity(NCE) | Oct 10, 2019 |
New Patient Population(NPP) | Nov 13, 2022 |
Drugs and Companies using SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES ingredient
NCE-1 date: 10 October, 2018
Market Authorisation Date: 15 October, 2014
Treatment: Use with ultrasound of the liver in adult and pediatric patients to characterize focal liver lesions
Dosage: FOR SUSPENSION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6197819 | UPJOHN | Gamma amino butyric acid analogs and optical isomers |
Dec, 2018
(6 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
USRE41920 | UPJOHN | Isobutylgaba and its derivatives for the treatment of pain |
Dec, 2018
(6 years ago) | |
US6197819 (Pediatric) | UPJOHN | Gamma amino butyric acid analogs and optical isomers |
Jun, 2019
(5 years ago) | |
USRE41920 (Pediatric) | UPJOHN | Isobutylgaba and its derivatives for the treatment of pain |
Jun, 2019
(5 years ago) | |
US8945620 | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
Nov, 2026
(1 year, 7 months from now) | |
US10022447 | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
Nov, 2026
(1 year, 7 months from now) | |
US9144559 | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
Nov, 2026
(1 year, 7 months from now) | |
US9144559 (Pediatric) | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
May, 2027
(2 years from now) | |
US10022447 (Pediatric) | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
May, 2027
(2 years from now) | |
US8945620 (Pediatric) | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
May, 2027
(2 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Oct 11, 2020 |
Pediatric Exclusivity(PED) | Apr 11, 2021 |
Drugs and Companies using PREGABALIN ingredient
Market Authorisation Date: 11 October, 2017
Treatment: Treatment of postherpetic neuralgia; Treatment of neuropathic pain associated with diabetic peripheral neuropathy
Dosage: TABLET, EXTENDED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6861409 | NOVO | Growth hormone secretagogues |
Aug, 2022
(2 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8192719 | NOVO | Methods and kits to diagnose growth hormone deficiency by oral administration of EP 1572 or EP 1573 compounds |
Oct, 2027
(2 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Dec 20, 2022 |
Orphan Drug Exclusivity(ODE-170) | Dec 20, 2024 |
Drugs and Companies using MACIMORELIN ACETATE ingredient
NCE-1 date: 20 December, 2021
Market Authorisation Date: 20 December, 2017
Treatment: A method for the diagnosis of adult growth hormone deficiency by measuring the level of growth hormone after oral administration of macimorelin
Dosage: FOR SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7342117 | APGDI | α-form or β-form crystal of acetanilide derivative |
Nov, 2023
(1 year, 4 months ago) | |
US6346532 | APGDI | Amide derivatives or salts thereof |
Mar, 2022
(3 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6346532 (Pediatric) | APGDI | Amide derivatives or salts thereof |
Sep, 2022
(2 years ago) | |
US7982049 | APGDI | α-form or β-form crystal of acetanilide derivative |
Nov, 2023
(1 year, 4 months ago) | |
US10058536 | APGDI | Pharmaceutical composition containing mirabegron |
Mar, 2036
(11 years from now) | |
US7342117 (Pediatric) | APGDI | α-form or β-form crystal of acetanilide derivative |
May, 2024
(10 months ago) | |
US7982049 (Pediatric) | APGDI | α-form or β-form crystal of acetanilide derivative |
May, 2024
(10 months ago) | |
US10058536 (Pediatric) | APGDI | Pharmaceutical composition containing mirabegron |
Sep, 2036
(11 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Mar 25, 2024 |
Pediatric Exclusivity(PED) | Sep 25, 2024 |
Drugs and Companies using MIRABEGRON ingredient
Market Authorisation Date: 25 March, 2021
Treatment: Treatment of neurogenic detrusor overactivity (ndo) in pediatric patients aged 3 years and older by administration of an extended-release suspension formulation of mirabegron
Dosage: FOR SUSPENSION, EXTENDED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7411070 | ASTRAZENECA LP | Form of S-omeprazole |
May, 2018
(6 years ago) | |
US6369085 | ASTRAZENECA LP | Form of S-omeprazole |
May, 2018
(6 years ago) | |
US5900424 | ASTRAZENECA LP | Omeprazole magnesium salt form |
May, 2016
(8 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6428810 (Pediatric) | ASTRAZENECA LP | Pharmaceutical formulation comprising omeprazole |
May, 2020
(4 years ago) | |
US7411070 (Pediatric) | ASTRAZENECA LP | Form of S-omeprazole |
Nov, 2018
(6 years ago) | |
US6369085 (Pediatric) | ASTRAZENECA LP | Form of S-omeprazole |
Nov, 2018
(6 years ago) | |
US6428810 | ASTRAZENECA LP | Pharmaceutical formulation comprising omeprazole |
Nov, 2019
(5 years ago) | |
US5900424 (Pediatric) | ASTRAZENECA LP | Omeprazole magnesium salt form |
Nov, 2016
(8 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
RTO(RTO) | Mar 28, 2017 |
Drugs and Companies using ESOMEPRAZOLE MAGNESIUM ingredient
Market Authorisation Date: 23 November, 2015
Treatment: Method of treating frequent heartburn by administering an esomeprazole magnesium formulation as claimed; Method of treating frequent heartburn by administering an esomeprazole magnesium trihydrate as ...
Dosage: TABLET, DELAYED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5849704 | NOVO NORDISK INC | Pharmaceutical formulation |
Dec, 2015
(9 years ago) | |
US5633352 | NOVO NORDISK INC | Biosynthetic human growth hormone |
May, 2014
(10 years ago) | |
US5849700 | NOVO NORDISK INC | Pharmaceutical formulation |
Dec, 2015
(9 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-572) | Oct 31, 2011 |
Orphan Drug Exclusivity(ODE) | May 31, 2014 |
Drugs and Companies using SOMATROPIN RECOMBINANT ingredient
Market Authorisation Date: 23 January, 2015
Treatment: The long term treatment of growth failure due to lack of adequate endogenous growth hormone secretion in children
Dosage: INJECTABLE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10376652 | NOVO NORDISK INC | Automatic injection device with a top release mechanism |
Jan, 2026
(9 months from now) | |
US10357616 | NOVO NORDISK INC | Injection device with an end of dose feedback mechanism |
Jan, 2026
(9 months from now) | |
US9457154 | NOVO NORDISK INC | Injection device with an end of dose feedback mechanism |
Sep, 2027
(2 years from now) | |
US7686786 | NOVO NORDISK INC | Dial-down mechanism for wind-up pen |
Aug, 2026
(1 year, 4 months from now) | |
US8841252 | NOVO NORDISK INC | Pharmaceutical formulation |
Dec, 2017
(7 years ago) | |
US9108002 | NOVO NORDISK INC | Automatic injection device with a top release mechanism |
Jan, 2026
(9 months from now) | |
US8684969 | NOVO NORDISK INC | Injection device with torsion spring and rotatable display |
Oct, 2025
(6 months from now) | |
US9486588 | NOVO NORDISK INC | Automatic injection device with reset feature |
Jan, 2022
(3 years ago) | |
US10220155 | NOVO NORDISK INC | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(1 year, 3 months from now) | |
US8672898 | NOVO NORDISK INC | Automatic injection device with reset feature |
Jan, 2022
(3 years ago) | |
US8920383 | NOVO NORDISK INC | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(1 year, 3 months from now) | |
US6899699 | NOVO NORDISK INC | Automatic injection device with reset feature |
Jan, 2022
(3 years ago) | |
US9861757 | NOVO NORDISK INC | Injection device with an end of dose feedback mechanism |
Jan, 2026
(9 months from now) | |
US6716198 | NOVO NORDISK INC | Injection device |
Jun, 2021
(3 years ago) | |
USRE46363 | NOVO NORDISK INC | Dial-down mechanism for wind-up pen |
Aug, 2026
(1 year, 4 months from now) | |
US9132239 | NOVO NORDISK INC | Dial-down mechanism for wind-up pen |
Feb, 2032
(6 years from now) | |
US9775953 | NOVO NORDISK INC | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(1 year, 3 months from now) | |
US9616180 | NOVO NORDISK INC | Automatic injection device with a top release mechanism |
Jan, 2026
(9 months from now) | |
US9687611 | NOVO NORDISK INC | Injection device with torsion spring and rotatable display |
Feb, 2027
(1 year, 10 months from now) | |
US7762994 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(10 months ago) | |
US8579869 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
Jun, 2023
(1 year, 8 months ago) | |
US5849704 | NOVO NORDISK INC | Pharmaceutical formulation |
Dec, 2015
(9 years ago) | |
US5849700 | NOVO NORDISK INC | Pharmaceutical formulation |
Dec, 2015
(9 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-572) | Oct 31, 2011 |
Orphan Drug Exclusivity(ODE) | May 31, 2014 |
Drugs and Companies using SOMATROPIN RECOMBINANT ingredient
Market Authorisation Date: 23 January, 2015
Treatment: Treatment of disorders responsive to growth hormone
Dosage: INJECTABLE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US5849704 | NOVO NORDISK INC | Pharmaceutical formulation |
Dec, 2015
(9 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10376652 | NOVO NORDISK INC | Automatic injection device with a top release mechanism |
Jan, 2026
(9 months from now) | |
US8684969 | NOVO NORDISK INC | Injection device with torsion spring and rotatable display |
Oct, 2025
(6 months from now) | |
US8841252 | NOVO NORDISK INC | Pharmaceutical formulation |
Dec, 2017
(7 years ago) | |
US5849700 | NOVO NORDISK INC | Pharmaceutical formulation |
Dec, 2015
(9 years ago) | |
US7686786 | NOVO NORDISK INC | Dial-down mechanism for wind-up pen |
Aug, 2026
(1 year, 4 months from now) | |
US9486588 | NOVO NORDISK INC | Automatic injection device with reset feature |
Jan, 2022
(3 years ago) | |
US9687611 | NOVO NORDISK INC | Injection device with torsion spring and rotatable display |
Feb, 2027
(1 year, 10 months from now) | |
US6899699 | NOVO NORDISK INC | Automatic injection device with reset feature |
Jan, 2022
(3 years ago) | |
US8672898 | NOVO NORDISK INC | Automatic injection device with reset feature |
Jan, 2022
(3 years ago) | |
US8579869 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
Jun, 2023
(1 year, 8 months ago) | |
US7762994 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(10 months ago) | |
US9861757 | NOVO NORDISK INC | Injection device with an end of dose feedback mechanism |
Jan, 2026
(9 months from now) | |
US9616180 | NOVO NORDISK INC | Automatic injection device with a top release mechanism |
Jan, 2026
(9 months from now) | |
USRE46363 | NOVO NORDISK INC | Dial-down mechanism for wind-up pen |
Aug, 2026
(1 year, 4 months from now) | |
US9132239 | NOVO NORDISK INC | Dial-down mechanism for wind-up pen |
Feb, 2032
(6 years from now) | |
US9457154 | NOVO NORDISK INC | Injection device with an end of dose feedback mechanism |
Sep, 2027
(2 years from now) | |
US8920383 | NOVO NORDISK INC | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(1 year, 3 months from now) | |
US10357616 | NOVO NORDISK INC | Injection device with an end of dose feedback mechanism |
Jan, 2026
(9 months from now) | |
US10220155 | NOVO NORDISK INC | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(1 year, 3 months from now) | |
US9775953 | NOVO NORDISK INC | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(1 year, 3 months from now) | |
US9108002 | NOVO NORDISK INC | Automatic injection device with a top release mechanism |
Jan, 2026
(9 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-572) | Oct 31, 2011 |
Orphan Drug Exclusivity(ODE) | May 31, 2014 |
Drugs and Companies using SOMATROPIN ingredient
Market Authorisation Date: 23 January, 2015
Treatment: Treatment of disorders responsive to growth hormone
Dosage: INJECTABLE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5849704 | NOVO NORDISK INC | Pharmaceutical formulation |
Dec, 2015
(9 years ago) | |
US5849700 | NOVO NORDISK INC | Pharmaceutical formulation |
Dec, 2015
(9 years ago) | |
US8841252 | NOVO NORDISK INC | Pharmaceutical formulation |
Dec, 2017
(7 years ago) | |
USRE43834 | NOVO NORDISK INC | Injection syringe |
Jan, 2019
(6 years ago) | |
USRE41956 | NOVO NORDISK INC | Dose setting limiter |
Jan, 2021
(4 years ago) | |
US6235004 | NOVO NORDISK INC | Injection syringe |
Jan, 2019
(6 years ago) | |
US6004297 | NOVO NORDISK INC | Injection syringe |
Jan, 2019
(6 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-572) | Oct 31, 2011 |
Orphan Drug Exclusivity(ODE) | May 31, 2014 |
Drugs and Companies using SOMATROPIN RECOMBINANT ingredient
Market Authorisation Date: 23 January, 2015
Treatment: The long term treatment of growth failure due to lack of adequate endogenous growth hormone secretion in children
Dosage: INJECTABLE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7541363 | KYOWA KIRIN | Microcrystal |
Nov, 2024
(4 months ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7727994 | KYOWA KIRIN | Methods of treating patients suffering from movement disorders |
Jan, 2023
(2 years ago) | |
US8318201 | KYOWA KIRIN | Method of stabilizing diarylvinylene compound |
Sep, 2027
(2 years from now) | |
US7727993 | KYOWA KIRIN | Administering adenosine A2A receptor antagonist to reduce or suppress side effects of parkinson's disease therapy |
Jan, 2028
(2 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Aug 27, 2024 |
Drugs and Companies using ISTRADEFYLLINE ingredient
NCE-1 date: 28 August, 2023
Market Authorisation Date: 27 August, 2019
Treatment: A method of reducing off time from l-dopa therapy, comprising administering, to a human patient with parkinson's disease, an effective amount of istradefylline, wherein the patient currently receives ...
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6992207 | ONCOPEPTIDES AB | Melphalan derivatives and their use as cancer chemotherapeutic drugs |
Jun, 2024
(9 months ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10543274 | ONCOPEPTIDES AB | Lyophilized preparation of cytotoxic dipeptides |
Apr, 2032
(7 years from now) | |
US11344622 | ONCOPEPTIDES AB | Lyophilized preparation of cytotoxic dipeptides |
Apr, 2032
(7 years from now) | |
US10285946 | ONCOPEPTIDES AB | Lyophilized preparations of melphalan flufenamide |
Apr, 2032
(7 years from now) | |
US10869928 | ONCOPEPTIDES AB | Lyophilized preparation of cytotoxic dipeptides |
Apr, 2032
(7 years from now) | |
US10322182 | ONCOPEPTIDES AB | Lyophilized preparation of cytotoxic dipeptides |
Apr, 2032
(7 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Feb 26, 2026 |
Orphan Drug Exclusivity(ODE-348) | Feb 26, 2028 |
Drugs and Companies using MELPHALAN FLUFENAMIDE HYDROCHLORIDE ingredient
NCE-1 date: 26 February, 2025
Market Authorisation Date: 26 February, 2021
Treatment: In combination with dexamethasone to treat relapsed or refractory multiple myeloma (refactory to at least 1 proteasome inhibitor, 1 immunomodulatory agent, and 1 anti-cd38 mab) in adults who received ...
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6458924 | NOVO | Derivatives of GLP-1 analogs |
Aug, 2017
(7 years ago) | |
US6268343 | NOVO | Derivatives of GLP-1 analogs |
Aug, 2022
(2 years ago) | |
US7235627 | NOVO | Derivatives of GLP-1 analogs |
Aug, 2017
(7 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6899699 | NOVO | Automatic injection device with reset feature |
Jan, 2022
(3 years ago) | |
US7686786 | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2026
(1 year, 4 months from now) | |
US8579869 | NOVO | Needle mounting system and a method for mounting a needle assembly |
Jun, 2023
(1 year, 8 months ago) | |
US6268343 (Pediatric) | NOVO | Derivatives of GLP-1 analogs |
Feb, 2023
(2 years ago) | |
US8579869 (Pediatric) | NOVO | Needle mounting system and a method for mounting a needle assembly |
Dec, 2023
(1 year, 2 months ago) | |
US9486588 | NOVO | Automatic injection device with reset feature |
Jan, 2022
(3 years ago) | |
US8846618 | NOVO | Stable formulation of modified GLP-1 |
Jun, 2022
(2 years ago) | |
US8672898 | NOVO | Automatic injection device with reset feature |
Jan, 2022
(3 years ago) | |
US8846618 (Pediatric) | NOVO | Stable formulation of modified GLP-1 |
Dec, 2022
(2 years ago) | |
US9486588 (Pediatric) | NOVO | Automatic injection device with reset feature |
Jul, 2022
(2 years ago) | |
US8672898 (Pediatric) | NOVO | Automatic injection device with reset feature |
Jul, 2022
(2 years ago) | |
US6899699 (Pediatric) | NOVO | Automatic injection device with reset feature |
Jul, 2022
(2 years ago) | |
US9968659 | NOVO | Liraglutide in cardiovascular conditions |
Jan, 2037
(11 years from now) | |
US8114833 | NOVO | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Aug, 2025
(4 months from now) | |
US7762994 | NOVO | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(10 months ago) | |
US10220155 | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(1 year, 3 months from now) | |
US9861757 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(9 months from now) | |
US11097063 | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(1 year, 3 months from now) | |
US9616180 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(9 months from now) | |
US9687611 | NOVO | Injection device with torsion spring and rotatable display |
Feb, 2027
(1 year, 10 months from now) | |
US9457154 | NOVO | Injection device with an end of dose feedback mechanism |
Sep, 2027
(2 years from now) | |
US11311679 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(9 months from now) | |
US8684969 | NOVO | Injection device with torsion spring and rotatable display |
Oct, 2025
(6 months from now) | |
US9775953 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(1 year, 3 months from now) | |
US8920383 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(1 year, 3 months from now) | |
US10357616 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(9 months from now) | |
US7762994 (Pediatric) | NOVO | Needle mounting system and a method for mounting a needle assembly |
Nov, 2024
(4 months ago) | |
US10376652 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(9 months from now) | |
US9132239 | NOVO | Dial-down mechanism for wind-up pen |
Feb, 2032
(6 years from now) | |
US11446443 | NOVO | Injection device with torsion spring and rotatable display |
Oct, 2025
(6 months from now) | |
US9108002 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(9 months from now) | |
US8920383 (Pediatric) | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jan, 2027
(1 year, 9 months from now) | |
USRE46363 (Pediatric) | NOVO | Dial-down mechanism for wind-up pen |
Feb, 2027
(1 year, 10 months from now) | |
US9457154 (Pediatric) | NOVO | Injection device with an end of dose feedback mechanism |
Mar, 2028
(2 years from now) | |
US9687611 (Pediatric) | NOVO | Injection device with torsion spring and rotatable display |
Aug, 2027
(2 years from now) | |
US9861757 (Pediatric) | NOVO | Injection device with an end of dose feedback mechanism |
Jul, 2026
(1 year, 3 months from now) | |
US9616180 (Pediatric) | NOVO | Automatic injection device with a top release mechanism |
Jul, 2026
(1 year, 3 months from now) | |
US9775953 (Pediatric) | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jan, 2027
(1 year, 9 months from now) | |
US9108002 (Pediatric) | NOVO | Automatic injection device with a top release mechanism |
Jul, 2026
(1 year, 3 months from now) | |
US9132239 (Pediatric) | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2032
(7 years from now) | |
US8114833 (Pediatric) | NOVO | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Feb, 2026
(10 months from now) | |
US8684969 (Pediatric) | NOVO | Injection device with torsion spring and rotatable display |
Apr, 2026
(1 year, 22 days from now) | |
US9968659 (Pediatric) | NOVO | Liraglutide in cardiovascular conditions |
Jul, 2037
(12 years from now) | |
US10220155 (Pediatric) | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jan, 2027
(1 year, 9 months from now) | |
USRE46363 | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2026
(1 year, 4 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jan 25, 2015 |
New Product(NP) | Jan 25, 2017 |
New Patient Population(NPP) | Dec 04, 2023 |
Drugs and Companies using LIRAGLUTIDE ingredient
NCE-1 date: 25 January, 2014
Market Authorisation Date: 23 December, 2014
Treatment: Cardiovascular outcomes trial of liraglutide 1.8 mg in patients with type 2 diabetes and cardiovascular disease; Method for chronic weight management by treating obesity
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6667314 | VIIV HLTHCARE | Tropane derivatives useful in therapy |
Aug, 2021
(3 years ago) | |
US6586430 | VIIV HLTHCARE | CCR5 modulators |
Dec, 2019
(5 years ago) | |
US7576097 | VIIV HLTHCARE | Tropane derivatives useful in therapy |
May, 2021
(3 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6667314 | VIIV HLTHCARE | Tropane derivatives useful in therapy |
Aug, 2021
(3 years ago) | |
US7576097 (Pediatric) | VIIV HLTHCARE | Tropane derivatives useful in therapy |
Nov, 2021
(3 years ago) | |
US7368460 (Pediatric) | VIIV HLTHCARE | Tropane derivatives useful in therapy |
May, 2023
(1 year, 10 months ago) | |
US6586430 | VIIV HLTHCARE | CCR5 modulators |
Dec, 2019
(5 years ago) | |
US7368460 | VIIV HLTHCARE | Tropane derivatives useful in therapy |
Nov, 2022
(2 years ago) | |
US7576097 | VIIV HLTHCARE | Tropane derivatives useful in therapy |
May, 2021
(3 years ago) | |
US6667314 (Pediatric) | VIIV HLTHCARE | Tropane derivatives useful in therapy |
Feb, 2022
(3 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Aug 06, 2012 |
New Patient Population(NPP) | Oct 30, 2023 |
New Product(NP) | Nov 04, 2019 |
New Strength(NS) | Nov 04, 2019 |
Pediatric Exclusivity(PED) | Apr 30, 2024 |
Drugs and Companies using MARAVIROC ingredient
NCE-1 date: 07 August, 2011
Market Authorisation Date: 04 November, 2016
Treatment: Method of treating patients infected with ccr5-tropic hiv-1
Dosage: TABLET; SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
USRE45313 | SANOFI-AVENTIS US | Exendin variant peptides |
Jul, 2020
(4 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9950039 | SANOFI-AVENTIS US | Insulin glargine/lixisenatide fixed ratio formulation |
Dec, 2035
(10 years from now) | |
US9827379 | SANOFI-AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(1 year, 26 days ago) | |
US9775954 | SANOFI-AVENTIS US | Pen-type injector |
Mar, 2024
(1 year, 26 days ago) | |
US8992486 | SANOFI-AVENTIS US | Pen-type injector |
Jun, 2024
(9 months ago) | |
US9011391 | SANOFI-AVENTIS US | Pen-type injector |
Mar, 2024
(1 year, 2 days ago) | |
US9821032 | SANOFI-AVENTIS US | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
May, 2032
(7 years from now) | |
US10029011 | SANOFI-AVENTIS US | Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine |
Nov, 2030
(5 years from now) | |
US9561331 | SANOFI-AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(6 months ago) | |
US9604009 | SANOFI-AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(7 months ago) | |
US9707176 | SANOFI-AVENTIS US | Pharmaceutical composition comprising a GLP-1 agonist and methionine |
Nov, 2030
(5 years from now) | |
US9604008 | SANOFI-AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(1 year, 26 days ago) | |
US9408979 | SANOFI-AVENTIS US | Pen-type injector |
Mar, 2024
(1 year, 26 days ago) | |
US7918833 | SANOFI-AVENTIS US | Pen-type injector |
Sep, 2027
(2 years from now) | |
US10117909 | SANOFI-AVENTIS US | Combination of an insulin and a GLP-1 agonist |
Oct, 2029
(4 years from now) | |
US9233211 | SANOFI-AVENTIS US | Relating to a pen-type injector |
Mar, 2024
(1 year, 26 days ago) | |
US8679069 | SANOFI-AVENTIS US | Pen-type injector |
Apr, 2025
(14 days from now) | |
US9526844 | SANOFI-AVENTIS US | Pen-type injector |
Mar, 2024
(1 year, 26 days ago) | |
US8603044 | SANOFI-AVENTIS US | Pen-type injector |
Mar, 2024
(1 year, 26 days ago) | |
US9533105 | SANOFI-AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(7 months ago) | |
US9717852 | SANOFI-AVENTIS US | Cartridge holder and pen-type injector |
Apr, 2033
(8 years from now) | |
US9526764 | SANOFI-AVENTIS US | Combination of an insulin and a GLP-1-agonist |
Oct, 2029
(4 years from now) | |
US8512297 | SANOFI-AVENTIS US | Pen-type injector |
Sep, 2024
(6 months ago) | |
US8556864 | SANOFI-AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(1 year, 25 days ago) | |
US9623189 | SANOFI-AVENTIS US | Relating to drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(7 months ago) | |
US9610409 | SANOFI-AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(1 year, 26 days ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Combination(NC) | Nov 21, 2019 |
New Chemical Entity Exclusivity(NCE) | Jul 27, 2021 |
Drugs and Companies using INSULIN GLARGINE; LIXISENATIDE ingredient
NCE-1 date: 27 July, 2020
Market Authorisation Date: 21 November, 2016
Treatment: Improvement in glycemic control in adults with type 2 diabetes mellitus inadequately controlled by lixisenatide in combination with metformin and a second oral antidiabetic drug; Improvement in glycem...
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
USRE39820 | BOEHRINGER INGELHEIM | Esters of thienyl carboxylic acids and amino alcohols and their quaternization products |
Jan, 2018
(7 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6149054 (Pediatric) | BOEHRINGER INGELHEIM | Mechanical counter for a metering apparatus |
Jun, 2017
(7 years ago) | |
US7246615 | BOEHRINGER INGELHEIM | Atomising nozzle and filter and spray generating device |
May, 2016
(8 years ago) | |
US7988001 | BOEHRINGER INGELHEIM | Container provided with a pressure equalization opening |
Aug, 2021
(3 years ago) | |
US7104470 | BOEHRINGER INGELHEIM | Device for producing high pressure in a fluid in miniature |
Oct, 2016
(8 years ago) | |
US6453795 | BOEHRINGER INGELHEIM | Locking mechanism for a spring-actuated device |
Dec, 2016
(8 years ago) | |
US6176242 | BOEHRINGER INGELHEIM | Method of treating manic depression by brain infusion |
May, 2016
(8 years ago) | |
USRE39820 (Pediatric) | BOEHRINGER INGELHEIM | Esters of thienyl carboxylic acids and amino alcohols and their quaternization products |
Jul, 2018
(6 years ago) | |
US5964416 | BOEHRINGER INGELHEIM | Device for producing high pressure in a fluid in miniature |
Oct, 2016
(8 years ago) | |
US6726124 | BOEHRINGER INGELHEIM | Device for producing high pressure in a fluid in miniature |
Oct, 2016
(8 years ago) | |
US6988496 | BOEHRINGER INGELHEIM | Cartridge for a liquid |
Feb, 2020
(5 years ago) | |
US6977042 | BOEHRINGER INGELHEIM | Microstructured filter |
Aug, 2018
(6 years ago) | |
US6988496 (Pediatric) | BOEHRINGER INGELHEIM | Cartridge for a liquid |
Aug, 2020
(4 years ago) | |
US6176442 | BOEHRINGER INGELHEIM | Device for mounting a component exposed to a pressurized fluid |
May, 2016
(8 years ago) | |
US6149054 | BOEHRINGER INGELHEIM | Mechanical counter for a metering apparatus |
Dec, 2016
(8 years ago) | |
US6846413 (Pediatric) | BOEHRINGER INGELHEIM | Microstructured filter |
Feb, 2019
(6 years ago) | |
US6846413 | BOEHRINGER INGELHEIM | Microstructured filter |
Aug, 2018
(6 years ago) | |
US5964416 (Pediatric) | BOEHRINGER INGELHEIM | Device for producing high pressure in a fluid in miniature |
Apr, 2017
(7 years ago) | |
US6453795 (Pediatric) | BOEHRINGER INGELHEIM | Locking mechanism for a spring-actuated device |
Jun, 2017
(7 years ago) | |
US7104470 (Pediatric) | BOEHRINGER INGELHEIM | Device for producing high pressure in a fluid in miniature |
Apr, 2017
(7 years ago) | |
US6726124 (Pediatric) | BOEHRINGER INGELHEIM | Device for producing high pressure in a fluid in miniature |
Apr, 2017
(7 years ago) | |
US7246615 (Pediatric) | BOEHRINGER INGELHEIM | Atomising nozzle and filter and spray generating device |
Dec, 2016
(8 years ago) | |
US6176442 (Pediatric) | BOEHRINGER INGELHEIM | Device for mounting a component exposed to a pressurized fluid |
Dec, 2016
(8 years ago) | |
US7802568 | BOEHRINGER INGELHEIM | Cartridge for a liquid |
Feb, 2019
(6 years ago) | |
US7802568 (Pediatric) | BOEHRINGER INGELHEIM | Cartridge for a liquid |
Aug, 2019
(5 years ago) | |
US6977042 (Pediatric) | BOEHRINGER INGELHEIM | Microstructured filter |
Feb, 2019
(6 years ago) | |
US7988001 (Pediatric) | BOEHRINGER INGELHEIM | Container provided with a pressure equalization opening |
Feb, 2022
(3 years ago) | |
US7396341 | BOEHRINGER INGELHEIM | Blocking device for a locking stressing mechanism having a spring-actuated output drive device |
Oct, 2026
(1 year, 6 months from now) | |
US7284474 | BOEHRINGER INGELHEIM | Piston-pumping system having o-ring seal properties |
Aug, 2024
(7 months ago) | |
US7837235 | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Mar, 2028
(2 years from now) | |
US7896264 | BOEHRINGER INGELHEIM | Microstructured high pressure nozzle with built-in filter function |
May, 2025
(a month from now) | |
US8733341 | BOEHRINGER INGELHEIM | Atomizer and method of atomizing fluid with a nozzle rinsing mechanism |
Oct, 2030
(5 years from now) | |
US9027967 | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Mar, 2027
(2 years from now) | |
US7896264 (Pediatric) | BOEHRINGER INGELHEIM | Microstructured high pressure nozzle with built-in filter function |
Nov, 2025
(7 months from now) | |
US7284474 (Pediatric) | BOEHRINGER INGELHEIM | Piston-pumping system having o-ring seal properties |
Feb, 2025
(30 days ago) | |
US7837235 (Pediatric) | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Sep, 2028
(3 years from now) | |
US7396341 (Pediatric) | BOEHRINGER INGELHEIM | Blocking device for a locking stressing mechanism having a spring-actuated output drive device |
Apr, 2027
(2 years from now) | |
US9027967 (Pediatric) | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Sep, 2027
(2 years from now) | |
US8733341 (Pediatric) | BOEHRINGER INGELHEIM | Atomizer and method of atomizing fluid with a nozzle rinsing mechanism |
Apr, 2031
(6 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Sep 15, 2018 |
New Patient Population(NPP) | Feb 15, 2020 |
Pediatric Exclusivity(PED) | Aug 15, 2020 |
Drugs and Companies using TIOTROPIUM BROMIDE ingredient
Market Authorisation Date: 15 September, 2015
Treatment: NA
Dosage: SPRAY, METERED
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8124643 | SIGA TECHNOLOGIES | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Jun, 2024
(9 months ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8530509 | SIGA TECHNOLOGIES | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Jun, 2024
(9 months ago) | |
US10576165 | SIGA TECHNOLOGIES | ST-246 liquid formulations and methods |
Aug, 2031
(6 years from now) | |
US8039504 | SIGA TECHNOLOGIES | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Jul, 2027
(2 years from now) | |
US9233097 | SIGA TECHNOLOGIES | ST-246 liquid formulations |
Aug, 2031
(6 years from now) | |
US8802714 | SIGA TECHNOLOGIES | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Jun, 2024
(9 months ago) | |
US7737168 | SIGA TECHNOLOGIES | Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Sep, 2031
(6 years from now) | |
US9907859 | SIGA TECHNOLOGIES | ST-246 liquid formulations and methods |
Aug, 2031
(6 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jul 13, 2023 |
Orphan Drug Exclusivity(ODE-200) | Jul 13, 2025 |
Drugs and Companies using TECOVIRIMAT ingredient
NCE-1 date: 13 July, 2022
Market Authorisation Date: 18 May, 2022
Treatment: Tpoxx is indicated for the treatment of human smallpox disease in adults and pediatric patients weighing at least 3 kg
Dosage: SOLUTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US5922695 | GILEAD | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
Jul, 2017
(7 years ago) | |
US5935946 | GILEAD | Nucleotide analog composition and synthesis method |
Jul, 2017
(7 years ago) | |
US5977089 | GILEAD | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jul, 2017
(7 years ago) | |
US5814639 | GILEAD | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Sep, 2015
(9 years ago) | |
US5914331 | GILEAD | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jul, 2017
(7 years ago) | |
US6703396 | GILEAD | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Mar, 2021
(4 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5814639 (Pediatric) | GILEAD | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Mar, 2016
(9 years ago) | |
US5977089 | GILEAD | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jul, 2017
(7 years ago) | |
US6043230 | GILEAD | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jul, 2017
(7 years ago) | |
US6642245 | GILEAD | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Nov, 2020
(4 years ago) | |
US5922695 (Pediatric) | GILEAD | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
Jan, 2018
(7 years ago) | |
US5935946 (Pediatric) | GILEAD | Nucleotide analog composition and synthesis method |
Jan, 2018
(7 years ago) | |
US5914331 (Pediatric) | GILEAD | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jan, 2018
(7 years ago) | |
US5977089 (Pediatric) | GILEAD | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jan, 2018
(7 years ago) | |
US6043230 (Pediatric) | GILEAD | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jan, 2018
(7 years ago) | |
US8716264 (Pediatric) | GILEAD | Compositions and methods for combination antiviral therapy |
Jul, 2024
(8 months ago) | |
US5814639 | GILEAD | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Sep, 2015
(9 years ago) | |
US5922695 | GILEAD | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
Jul, 2017
(7 years ago) | |
US5935946 | GILEAD | Nucleotide analog composition and synthesis method |
Jul, 2017
(7 years ago) | |
US6642245 (Pediatric) | GILEAD | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
May, 2021
(3 years ago) | |
US6703396 (Pediatric) | GILEAD | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Sep, 2021
(3 years ago) | |
US5914331 | GILEAD | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jul, 2017
(7 years ago) | |
US8592397 | GILEAD | Compositions and methods for combination antiviral therapy |
Jan, 2024
(1 year, 2 months ago) | |
US9744181 | GILEAD | Compositions and methods for combination antiviral therapy |
Jan, 2024
(1 year, 2 months ago) | |
US6703396 | GILEAD | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Mar, 2021
(4 years ago) | |
US9457036 | GILEAD | Compositions and methods for combination antiviral therapy |
Jan, 2024
(1 year, 2 months ago) | |
US8716264 | GILEAD | Compositions and methods for combination antiviral therapy |
Jan, 2024
(1 year, 2 months ago) |
Drugs and Companies using EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE ingredient
Market Authorisation Date: 10 March, 2016
Treatment: Treatment of hiv-1 infection in pediatric patients 12 years of age and older; Method of treatment of adults infected with hiv-1; Treatment of hiv; Treatment of hiv infection; Prophylaxis of hiv-1 infe...
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
USRE46417 | COVIS | Quinuclidine derivatives and their use as muscarinic M3 receptor ligands |
Feb, 2025
(a month ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10034867 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(4 years ago) | |
US9056100 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(4 years ago) | |
US9333195 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(4 years ago) | |
US5840279 | COVIS | Pharmaceutical powder cartridge with integrated metering device and inhaler for powdered medicaments |
Jun, 2016
(8 years ago) | |
US6750226 | COVIS | Quinuclidine derivatives and their use as muscarinic M3 receptor ligands |
Sep, 2020
(4 years ago) | |
US7078412 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(4 years ago) | |
US10588895 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(4 years ago) | |
US6071498 | COVIS | Inhaler for powdered medicaments |
Jun, 2016
(8 years ago) | |
US6681768 | COVIS | Powder formulation disintegrating system and method for dry powder inhalers |
Aug, 2022
(2 years ago) | |
US11000517 | COVIS | Dosage and formulation |
Mar, 2029
(3 years from now) | |
US8051851 | COVIS | Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhaler |
Apr, 2027
(2 years from now) | |
US10085974 | COVIS | Dosage and formulation |
Mar, 2029
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jul 23, 2017 |
M(M-256) | Mar 29, 2022 |
Drugs and Companies using ACLIDINIUM BROMIDE ingredient
NCE-1 date: 23 July, 2016
Market Authorisation Date: 23 July, 2012
Treatment: Maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (copd); Maintenance treatment of chronic obstructive pulmonary disease (copd); Treatment of a respiratory di...
Dosage: POWDER, METERED
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6878721 | NOVARTIS | Beta2-adrenoceptor agonists |
Feb, 2025
(a month ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8029768 | NOVARTIS | Treatment of respiratory diseases |
Apr, 2021
(3 years ago) | |
US7820694 | NOVARTIS | Beta-2-adrenoreceptor agonists |
Jun, 2020
(4 years ago) | |
US8658673 | NOVARTIS | BETA2-adrenoreceptor agonists |
Jun, 2020
(4 years ago) | |
US6582678 | NOVARTIS | Carrier particles for use in dry powder inhalers |
Apr, 2018
(6 years ago) | |
US6521260 | NOVARTIS | Carrier particles for use in dry powder inhalers |
Jan, 2016
(9 years ago) | |
US8580306 | NOVARTIS | Particles for use in a pharmaceutical composition |
Jun, 2021
(3 years ago) | |
US9962338 | NOVARTIS | Method of making particles for use in a pharmaceutical composition |
Jun, 2021
(3 years ago) | |
US8796307 | NOVARTIS | Beta2-adrenoreceptor agonists |
Jun, 2020
(4 years ago) | |
US8283362 | NOVARTIS | Beta-2-adrenoreceptor agonists |
Jun, 2020
(4 years ago) | |
US7229607 | NOVARTIS | Treatment of respiratory disease |
Apr, 2021
(3 years ago) | |
US7736670 | NOVARTIS | Method of making particles for use in a pharmaceutical composition |
Jun, 2021
(3 years ago) | |
US8067437 | NOVARTIS | Beta-2-adrenoreceptor agonists |
Jun, 2020
(4 years ago) | |
US8956661 | NOVARTIS | Method of making composite particles for use in pharmaceutical compositions and composite particles and compositions thereof |
Jun, 2021
(3 years ago) | |
US8435567 | NOVARTIS | Pharmaceutical compositions of hydrophobic surface-modified active substance microparticles for inhalation |
Jun, 2021
(3 years ago) | |
US8303991 | NOVARTIS | Method of making particles for use in a pharmaceutical composition |
Jun, 2021
(3 years ago) | |
US8048451 | NOVARTIS | Pharmaceutical compositions for inhalation |
Jun, 2021
(3 years ago) | |
US9931304 | NOVARTIS | Method of making particles for use in a pharmaceutical composition |
Jun, 2021
(3 years ago) | |
US8182838 | NOVARTIS | Dry powder composition comprising co-jet milled particles for pulmonary inhalation |
Oct, 2028
(3 years from now) | |
US8479730 | NOVARTIS | Inhaler device |
Oct, 2028
(3 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jul 01, 2016 |
New Product(NP) | Oct 29, 2018 |
Drugs and Companies using GLYCOPYRROLATE; INDACATEROL MALEATE ingredient
NCE-1 date: 02 July, 2015
Market Authorisation Date: 29 October, 2015
Treatment: Long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd)
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8188146 | AMARIN PHARMS | Highly purified ethyl EPA and other EPA derivatives |
Jan, 2020
(5 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8524698 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(4 years from now) | |
US8188146 | AMARIN PHARMS | Highly purified ethyl EPA and other EPA derivatives |
Jan, 2020
(5 years ago) | |
US8377920 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(4 years from now) | |
US8367652 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(4 years from now) | |
US8399446 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(4 years from now) | |
US8431560 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(4 years from now) | |
US8501225 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
US8618166 | AMARIN PHARMS | Methods of treating mixed dyslipidemia |
Apr, 2030
(5 years from now) | |
US8623406 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
US8642077 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
US8669245 | AMARIN PHARMS | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
Jun, 2030
(5 years from now) | |
US8680144 | AMARIN PHARMS | Methods of treating mixed dyslipidemia |
Feb, 2030
(4 years from now) | |
US8703185 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
US8691871 | AMARIN PHARMS | Methods of treating mixed dyslipidemia |
Apr, 2030
(5 years from now) | |
US8709475 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
US8710041 | AMARIN PHARMS | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy |
Jun, 2030
(5 years from now) | |
US9693984 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(8 years from now) | |
US9623001 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(8 years from now) | |
US9693985 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(8 years from now) | |
US9693986 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(8 years from now) | |
US10010517 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
US9918954 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(8 years from now) | |
US10278936 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(8 years from now) | |
US10278937 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(8 years from now) | |
US10383840 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
Jun, 2033
(8 years from now) | |
US8440650 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(4 years from now) | |
US8415335 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(4 years from now) | |
US8563608 | AMARIN PHARMS | Methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
Apr, 2030
(5 years from now) | |
US8293728 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(4 years from now) | |
US8314086 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(4 years from now) | |
US8318715 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(4 years from now) | |
US8357677 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(4 years from now) | |
US9700537 | AMARIN PHARMS | Composition for preventing the occurrence of cardiovascular event in multiple risk patient |
May, 2027
(2 years from now) | |
US9198892 | AMARIN PHARMS | Composition and/or method for preventing onset and/or recurrence of cardiovascular events |
Sep, 2027
(2 years from now) | |
US11154526 | AMARIN PHARMS | Methods of treating mixed dyslipidemia |
Apr, 2030
(5 years from now) | |
US10568861 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
Jun, 2033
(8 years from now) | |
US8410086 | AMARIN PHARMS | Compositions and methods for lowering triglycerides |
Jun, 2030
(5 years from now) | |
US8454994 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
US8455472 | AMARIN PHARMS | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
Jun, 2030
(5 years from now) | |
US8617593 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
US9603826 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(8 years from now) | |
US10668042 | AMARIN PHARMS | Methods of reducing the risk of cardiovascular events in a subject |
Jun, 2033
(8 years from now) | |
US10555925 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
Jun, 2033
(8 years from now) | |
US10555924 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
Jun, 2033
(8 years from now) | |
US8551521 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
US10576054 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
Jun, 2033
(8 years from now) | |
US8617594 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
US11717504 | AMARIN PHARMS | Methods of reducing the risk of cardiovascular events in a subject |
Apr, 2030
(5 years from now) | |
US8293727 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(4 years from now) | |
US10792270 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
Jun, 2033
(8 years from now) | |
US10786478 | AMARIN PHARMS | Methods of reducing the risk of cardiovascular events in a subject |
Jun, 2033
(8 years from now) | |
US10792267 | AMARIN PHARMS | Methods of treating mixed dyslipidemia |
Apr, 2030
(5 years from now) | |
US10842768 | AMARIN PHARMS | Compositions and methods for lowering triglycerides |
Jun, 2030
(5 years from now) | |
US10842766 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
US10881632 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
US10894028 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
Jun, 2033
(8 years from now) | |
US8445003 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
US11103477 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
US11000499 | AMARIN PHARMS | Methods of reducing the risk of cardiovascular events in a subject |
Jun, 2033
(8 years from now) | |
US11116742 | AMARIN PHARMS | Methods of reducing the risk of cardiovascular events in a subject |
Jun, 2033
(8 years from now) | |
US8518929 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(4 years from now) | |
US11213504 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
US8298554 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
US8546372 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(4 years from now) | |
US8445013 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
US8426399 | AMARIN PHARMS | Methods of treating hypertriglyceridemia |
Feb, 2030
(4 years from now) | |
US12171738 | AMARIN PHARMS | Compositions and methods for lowering triglycerides |
Feb, 2030
(4 years from now) | |
US9610272 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(8 years from now) | |
US10278935 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(8 years from now) | |
US10265287 | AMARIN PHARMS | Methods of reducing triglycerides and LDL-C |
Apr, 2030
(5 years from now) | |
US11369582 | AMARIN PHARMS | Methods of reducing the risk of cardiovascular events in a subject |
Jun, 2033
(8 years from now) | |
US11298333 | AMARIN PHARMS | Methods of reducing the risk of cardiovascular events in a subject |
Jun, 2033
(8 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Jul 26, 2015 |
New Chemical Entity Exclusivity(NCE) | Jul 26, 2017 |
New Indication(I-819) | Dec 13, 2022 |
Drugs and Companies using ICOSAPENT ETHYL ingredient
NCE-1 date: 26 July, 2016
Market Authorisation Date: 26 July, 2012
Treatment: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia; Use of vascepa to treat mixed dyslipidemia in an adult patient with elevated triglyceride (tg) levels (>=150 mg/dl) ...
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6717015 | ALMATICA | Venlafaxine besylate |
Mar, 2023
(2 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7776358 | ALMATICA | Extended release venlafaxine besylate tablets |
May, 2028
(3 years from now) |
Drugs and Companies using VENLAFAXINE BESYLATE ingredient
Market Authorisation Date: 29 June, 2022
Treatment: Treatment of depression and generalized anxiety disorder
Dosage: TABLET, EXTENDED RELEASE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8752543 | GLAXOSMITHKLINE | Fluid dispensing device |
Apr, 2026
(1 year, 7 days from now) | |
US6858596 | GLAXOSMITHKLINE | Formulation containing anti-inflammatory androstane derivative |
Aug, 2021
(3 years ago) | |
US7101866 | GLAXOSMITHKLINE | Anti-inflammatory androstane derivative |
Aug, 2021
(3 years ago) | |
US7541350 | GLAXOSMITHKLINE | Formulation containing anti-inflammatory androstane derivative |
Aug, 2021
(3 years ago) | |
US8062264 | GLAXOSMITHKLINE | Fluid dispensing device |
Apr, 2026
(1 year, 7 days from now) | |
US9320862 | GLAXOSMITHKLINE | Fluid dispensing device |
Nov, 2024
(4 months ago) | |
US8147461 | GLAXOSMITHKLINE | Fluid dispensing device |
Mar, 2025
(18 days ago) | |
US8347879 | GLAXOSMITHKLINE | Fluid dispensing device |
Apr, 2027
(2 years from now) |
Drugs and Companies using FLUTICASONE FUROATE ingredient
Market Authorisation Date: 27 April, 2007
Treatment: The treatment of the symptoms of seasonal and perennial allergic rhinitis in patients 2 years of age and older; Treatment of rhinitis comprising the nasal application of a pharmaceutical formulation a...
Dosage: SPRAY, METERED
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7662787 | TAKEDA PHARMS USA | Abuse resistant lysine amphetamine compounds |
Feb, 2023
(2 years ago) | |
US7659253 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(2 years ago) | |
US7655630 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(2 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7671030 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(2 years ago) | |
US7659254 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(2 years ago) | |
US7662788 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(1 year, 7 months ago) | |
US7713936 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(2 years ago) | |
US7700561 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(1 year, 7 months ago) | |
US7723305 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(1 year, 7 months ago) | |
US7659253 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(2 years ago) | |
US7687467 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Apr, 2023
(1 year, 11 months ago) | |
US7723305 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(2 years ago) | |
US7718619 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(2 years ago) | |
US7671031 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(2 years ago) | |
US7662788 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(2 years ago) | |
US7678770 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Mar, 2023
(2 years ago) | |
US7105486 | TAKEDA PHARMS USA | Abuse-resistant amphetamine compounds |
Jun, 2023
(1 year, 8 months ago) | |
US7678771 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Mar, 2023
(2 years ago) | |
US7674774 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Mar, 2023
(2 years ago) | |
US7655630 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(2 years ago) | |
US7671030 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(1 year, 7 months ago) | |
US7718619 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(1 year, 7 months ago) | |
US7700561 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Jun, 2023
(1 year, 8 months ago) | |
US7687466 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(2 years ago) | |
US7662787 | TAKEDA PHARMS USA | Abuse resistant lysine amphetamine compounds |
Feb, 2023
(2 years ago) | |
US7223735 | TAKEDA PHARMS USA | Abuse resistant lysine amphetamine compounds |
Jun, 2023
(1 year, 8 months ago) | |
US7662787 (Pediatric) | TAKEDA PHARMS USA | Abuse resistant lysine amphetamine compounds |
Aug, 2023
(1 year, 7 months ago) | |
US7671031 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(1 year, 7 months ago) | |
US7674774 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(1 year, 7 months ago) | |
US7713936 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(1 year, 7 months ago) | |
US7105486 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine compounds |
Aug, 2023
(1 year, 7 months ago) | |
US7223735 (Pediatric) | TAKEDA PHARMS USA | Abuse resistant lysine amphetamine compounds |
Aug, 2023
(1 year, 7 months ago) | |
US7655630 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(1 year, 7 months ago) | |
US7659253 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(1 year, 7 months ago) | |
US7659254 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(1 year, 7 months ago) | |
US7678770 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(1 year, 7 months ago) | |
US7678771 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(1 year, 7 months ago) | |
US7687466 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(1 year, 7 months ago) | |
US7687467 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(1 year, 7 months ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Feb 23, 2012 |
M(M-82) | Apr 05, 2013 |
New Patient Population(NPP) | Nov 10, 2013 |
New Indication(I-645) | Jan 31, 2015 |
New Indication(I-703) | Jan 30, 2018 |
M(M-188) | Oct 14, 2019 |
Drugs and Companies using LISDEXAMFETAMINE DIMESYLATE ingredient
Market Authorisation Date: 28 January, 2017
Treatment: For the treatment of attention deficit hyperactivity disorder (adhd); Treatment of attention deficit hyperactivity disorder (adhd) in adults; Indicated for the treatment of attention-deficit/hyperacti...
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7585860 | JANSSEN PHARMS | Substituted oxazolidinones and their use in the field of blood coagulation |
Dec, 2020
(4 years ago) | |
US7157456 | JANSSEN PHARMS | Substituted oxazolidinones and their use in the field of blood coagulation |
Aug, 2024
(6 months ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7585860 | JANSSEN PHARMS | Substituted oxazolidinones and their use in the field of blood coagulation |
Dec, 2020
(4 years ago) | |
US7592339 | JANSSEN PHARMS | Substituted oxazolidinones and their use in the field of blood coagulation |
Dec, 2020
(4 years ago) | |
US9415053 | JANSSEN PHARMS | Solid, orally administrable pharmaceutical composition |
Nov, 2024
(4 months ago) | |
US10828310 | JANSSEN PHARMS | Reducing the risk of cardiovascular events |
Jan, 2039
(13 years from now) | |
US9539218 | JANSSEN PHARMS | Prevention and treatment of thromboembolic disorders |
Feb, 2034
(8 years from now) | |
US7157456 (Pediatric) | JANSSEN PHARMS | Substituted oxazolidinones and their use in the field of blood coagulation |
Feb, 2025
(28 days ago) | |
US9415053 (Pediatric) | JANSSEN PHARMS | Solid, orally administrable pharmaceutical composition |
May, 2025
(a month from now) | |
US9539218 (Pediatric) | JANSSEN PHARMS | Prevention and treatment of thromboembolic disorders |
Aug, 2034
(9 years from now) | |
US10828310 (Pediatric) | JANSSEN PHARMS | Reducing the risk of cardiovascular events |
Jul, 2039
(14 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-643) | Nov 04, 2014 |
New Indication(I-660) | Nov 02, 2015 |
New Indication(I-661) | Nov 02, 2015 |
New Indication(I-662) | Nov 02, 2015 |
New Chemical Entity Exclusivity(NCE) | Jul 01, 2016 |
New Dosing Schedule(D-168) | Oct 27, 2020 |
New Indication(I-824) | Oct 11, 2021 |
New Indication(I-810) | Oct 11, 2022 |
M(M-284) | Mar 10, 2023 |
New Indication(I-867) | Aug 23, 2024 |
New Product(NP) | Dec 20, 2024 |
Pediatric Exclusivity(PED) | Jun 20, 2025 |
Drugs and Companies using RIVAROXABAN ingredient
NCE-1 date: 24 February, 2024
Market Authorisation Date: 11 October, 2018
Treatment: Reduction in the risk of recurrence of deep vein thrombosis (dvt) and pulmonary embolism; Prophylaxis of deep vein thrombosis (dvt); Treatment of venous thromboembolism (vte) and the reduction in the ...
Dosage: TABLET; FOR SUSPENSION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9839631 | HATCHTECH | Methods and compositions for controlling ectoparasites |
Jul, 2024
(8 months ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10292389 | HATCHTECH | Pediculicidal composition |
Dec, 2034
(9 years from now) | |
US8212038 | HATCHTECH | Methods and compositions for controlling ectoparasites |
Jul, 2024
(8 months ago) | |
US9357783 | HATCHTECH | Methods and compositions for controlling ectoparasites |
Jul, 2024
(8 months ago) | |
US7812163 | HATCHTECH | Methods and compositions for controlling ectoparasites |
Oct, 2026
(1 year, 6 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jul 24, 2025 |
Drugs and Companies using ABAMETAPIR ingredient
NCE-1 date: 24 July, 2024
Market Authorisation Date: 24 July, 2020
Treatment: Topical treatment of head lice infestation in patients 6 months of age and older
Dosage: LOTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6335447 | FERRER INTERNACIONAL | Quinolonecarboxylic acid derivatives or salts thereof |
Nov, 2023
(1 year, 4 months ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9399014 | FERRER INTERNACIONAL | Pharmaceutical topical compositions |
Dec, 2029
(4 years from now) | |
US9180200 | FERRER INTERNACIONAL | Pharmaceutical topical compositions |
Jan, 2032
(6 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Dec 11, 2022 |
Drugs and Companies using OZENOXACIN ingredient
NCE-1 date: 11 December, 2021
Market Authorisation Date: 11 December, 2017
Treatment: Treatment of impetigo due to staphylococcus aureus or streptococcus pyogenes
Dosage: CREAM
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6432948 | FONSECA BIOSCIENCES | Use of 7-(2-oxa-5,8-diazabicylco[4.3.0]non-8-yl)-quinolone carboxylic acid and naphthyridon carboxylic acid derivatives for the treatment of heliobacter pylori infections and associated gastroduodenal diseases |
Apr, 2017
(7 years ago) | |
US6133260 | FONSECA BIOSCIENCES | Use of 7-(2-oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-quinolone carboxylic acid and naphthyridon carboxylic acid derivatives for the treatment of Helicobacter pylori infections and associated gastroduodenal diseases |
Apr, 2017
(7 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8536167 | FONSECA BIOSCIENCES | Methods for treating ophthalmic, otic, or nasal infections |
Aug, 2031
(6 years from now) | |
US9993483 | FONSECA BIOSCIENCES | Compositions and methods for treating ophthalmic, octic, or nasal infections |
Jul, 2030
(5 years from now) | |
US9504691 | FONSECA BIOSCIENCES | Finafloxacin suspension compositions |
Nov, 2033
(8 years from now) | |
US9119859 | FONSECA BIOSCIENCES | Methods for treating otic infections |
Jul, 2030
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Dec 17, 2019 |
Pediatric Exclusivity(PED) | Jun 17, 2020 |
Drugs and Companies using FINAFLOXACIN ingredient
NCE-1 date: 18 June, 2019
Market Authorisation Date: 17 December, 2014
Treatment: Treatment of acute otitis externa
Dosage: SUSPENSION/DROPS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7235567 | KEY THERAP | Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist |
Jun, 2021
(3 years ago) | |
US7304078 | KEY THERAP | Thrombin receptor antagonists |
Dec, 2027
(2 years from now) | |
US7713999 | KEY THERAP | Thrombin receptor antagonists |
May, 2024
(9 months ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | May 08, 2019 |
Drugs and Companies using VORAPAXAR SULFATE ingredient
NCE-1 date: 08 May, 2018
Market Authorisation Date: 08 May, 2014
Treatment: Reduction of thrombotic cardiovascular events; Reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (mi) or with peripheral arterial disease (pad)
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6559305 | PFIZER | Linezolid—crystal form II |
Jan, 2021
(4 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6559305 | PFIZER | Linezolid—crystal form II |
Jan, 2021
(4 years ago) | |
US6559305 (Pediatric) | PFIZER | Linezolid—crystal form II |
Jul, 2021
(3 years ago) | |
US5688792 | PFIZER | Substituted oxazine and thiazine oxazolidinone antimicrobials |
Nov, 2014
(10 years ago) | |
US5688792 (Pediatric) | PFIZER | Substituted oxazine and thiazine oxazolidinone antimicrobials |
May, 2015
(9 years ago) |
Drugs and Companies using LINEZOLID ingredient
Market Authorisation Date: 18 April, 2000
Treatment: Treatment of microbial infections
Dosage: SOLUTION